[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f4pqfoqRc0XdYPSsXuA_mIOGDAou1kUbIzOwW09WvOlk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":81,"rows":88},"Kafrelsheikh University",[4],265,false,98,35,152371,48,162,[14,17,20,23,26,29,31,33],{"name":15,"count":16},"Ischemic Stroke",21,{"name":18,"count":19},"Dexmedetomidine",11,{"name":21,"count":22},"Dental Implant Failed",8,{"name":24,"count":25},"Erector Spinae Plane Block",6,{"name":27,"count":28},"Migraine Disorders",5,{"name":30,"count":28},"COVID-19",{"name":32,"count":28},"Analgesia",{"name":34,"count":35},"Alveolar Bone Loss",4,[37,42,46,51,55,60,64,68,72,76],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT06653946","the Predictors of Hemorrhagic Transformation Subtypes in Acute Embolic Stroke Patients","2024-07-01","Alteplase",{"nctId":43,"briefTitle":44,"date":40,"intervention":45},"NCT06485726","Valproate Versus Propranolol in Migraine","Valproic Acid 500 MG",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06531122","Rivaroxaban Versus Apixaban in Cerebral Venous Thrombosis","2024-09-01","Apixaban 5MG",{"nctId":52,"briefTitle":53,"date":49,"intervention":54},"NCT06551415","Dabigatran Versus Apixaban in Cerebral Venous Thrombosis","Dabigatran Etexilate 150mg",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06591312","Combining Aspirin With Ticagrelor or Clopidogrel in Minor Stroke or TIA","2024-09-10","Ticagrelor 90 MG",{"nctId":61,"briefTitle":62,"date":63,"intervention":59},"NCT06591390","Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA","2024-09-15",{"nctId":65,"briefTitle":66,"date":63,"intervention":67},"NCT06591299","Combining Aspirin With Cilostazol or Clopidogrel in Minor Stroke or TIA","Cilostazol 100 MG",{"nctId":69,"briefTitle":70,"date":71,"intervention":67},"NCT06591351","Combining Aspirin With Cilostazol or Clopidogrel in Large-vessel Minor Stroke or TIA","2024-09-30",{"nctId":73,"briefTitle":74,"date":75,"intervention":59},"NCT06196047","Ticagrelor Versus Cilostazol in Minor Ischemic Stroke or TIA","2024-12-20",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT06509503","Impact of Combined Oral Contraceptive Pills on Migraine","2025-05-15","Combined oral contraceptive",[82,83,84,85,86,87],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[89,138,179,201,219,246,264,350,417,459,494,524,551,578,600,629,647,665,683,701,719,737,765,790,808,834,859,889,907,925,943,970,996,1023,1041,1066,1084,1102,1127,1155,1173,1201,1219,1246,1264,1290,1308,1335,1353,1391,1417,1435,1463,1481,1499,1527,1545,1563,1593,1611,1629,1647,1665,1683,1711,1729,1747,1774,1792,1819,1837,1855,1873,1901,1919,1945,1963,1988,2006,2035,2053,2071,2096,2114,2139,2157,2175,2200,2223,2241,2293,2326,2348,2383,2401,2427,2445,2470,2488,2515,2533,2551,2569,2587,2605,2631,2649,2667,2685,2703,2721,2745,2763,2781,2809,2827,2845,2863,2885,2903,2925,2943,2961,2979,2997,3025,3043,3068,3086,3109,3127,3154,3172,3193,3218,3236,3260,3278,3300,3327,3345,3363,3390,3428,3450,3476,3513,3536,3554,3578,3605,3623,3641,3666,3690,3716,3739,3757,3780,3798,3824,3849,3867,3885,3903,3928,3952],{"intervention":90,"totalTrials":91,"cells":92},"Propranolol",3,{"EARLY_PHASE1":93,"PHASE1":96,"PHASE2":98,"PHASE3":100,"PHASE4":126,"NA":136},{"trials":94,"activeCount":95},[],0,{"trials":97,"activeCount":95},[],{"trials":99,"activeCount":95},[],{"trials":101,"activeCount":95},[102,115],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":113},"NCT06361446","Zonisamide Versus Propranolol in Migraine","UNKNOWN",[85],"2025-03-30","2025-04-20","2024-03-29",600,[112],"Migraine",[114,90],"Zonisamide 50 MG",{"nctId":116,"briefTitle":117,"status":118,"phases":119,"primaryCompletion":120,"completion":121,"start":122,"enrollment":110,"conditions":123,"interventions":124},"NCT05851781","Lacosamide Versus Propranolol in Migraine","COMPLETED",[85],"2023-07-30","2023-08-30","2022-06-01",[27],[125,90],"Lacosamide",{"trials":127,"activeCount":135,"soonestReadout":40},[128],{"nctId":43,"briefTitle":44,"status":129,"phases":130,"primaryCompletion":40,"completion":131,"start":132,"enrollment":110,"conditions":133,"interventions":134},"RECRUITING",[86],"2024-07-05","2023-01-23",[27],[45,90],1,{"trials":137,"activeCount":95},[],{"intervention":41,"totalTrials":91,"cells":139},{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":148,"NA":177},{"trials":141,"activeCount":95},[],{"trials":143,"activeCount":95},[],{"trials":145,"activeCount":95},[],{"trials":147,"activeCount":95},[],{"trials":149,"activeCount":135,"soonestReadout":40},[150,161,168],{"nctId":151,"briefTitle":152,"status":118,"phases":153,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":160},"NCT06058884","Predictors of AIS Unfavorable Outcomes",[86],"2023-06-03","2023-06-29","2022-01-03",592,[15,159],"Alteplase Adverse Reaction",[41],{"nctId":38,"briefTitle":39,"status":129,"phases":162,"primaryCompletion":40,"completion":163,"start":164,"enrollment":165,"conditions":166,"interventions":167},[86],"2024-11-01","2022-07-01",716,[15,159],[41,41],{"nctId":169,"briefTitle":170,"status":118,"phases":171,"primaryCompletion":172,"completion":173,"start":174,"enrollment":110,"conditions":175,"interventions":176},"NCT06337175","Predictors of Post-alteplase Hemorrhagic Transformation of Brain Infarction",[86],"2023-10-30","2024-04-30","2021-06-01",[15,159],[41,41],{"trials":178,"activeCount":95},[],{"intervention":80,"totalTrials":135,"cells":180},{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":187,"PHASE4":189,"NA":199},{"trials":182,"activeCount":95},[],{"trials":184,"activeCount":95},[],{"trials":186,"activeCount":95},[],{"trials":188,"activeCount":95},[],{"trials":190,"activeCount":135,"soonestReadout":79},[191],{"nctId":77,"briefTitle":78,"status":129,"phases":192,"primaryCompletion":79,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":197},[86],"2025-07-30","2024-07-15",400,[112],[80,198],"Vaginal Ring",{"trials":200,"activeCount":95},[],{"intervention":198,"totalTrials":135,"cells":202},{"EARLY_PHASE1":203,"PHASE1":205,"PHASE2":207,"PHASE3":209,"PHASE4":211,"NA":217},{"trials":204,"activeCount":95},[],{"trials":206,"activeCount":95},[],{"trials":208,"activeCount":95},[],{"trials":210,"activeCount":95},[],{"trials":212,"activeCount":135,"soonestReadout":79},[213],{"nctId":77,"briefTitle":78,"status":129,"phases":214,"primaryCompletion":79,"completion":193,"start":194,"enrollment":195,"conditions":215,"interventions":216},[86],[112],[80,198],{"trials":218,"activeCount":95},[],{"intervention":220,"totalTrials":135,"cells":221},"Misoprostol",{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":228,"PHASE4":230,"NA":244},{"trials":223,"activeCount":95},[],{"trials":225,"activeCount":95},[],{"trials":227,"activeCount":95},[],{"trials":229,"activeCount":95},[],{"trials":231,"activeCount":135,"soonestReadout":236},[232],{"nctId":233,"briefTitle":234,"status":129,"phases":235,"primaryCompletion":236,"completion":237,"start":238,"enrollment":239,"conditions":240,"interventions":243},"NCT06946914","Misoprostol Before Caesarean Section",[86],"2025-06-01","2025-08-01","2024-06-01",160,[220,241,242],"Respiratory Distress Syndrome (RDS) of Neonate","Caesarean Section",[220],{"trials":245,"activeCount":95},[],{"intervention":45,"totalTrials":135,"cells":247},{"EARLY_PHASE1":248,"PHASE1":250,"PHASE2":252,"PHASE3":254,"PHASE4":256,"NA":262},{"trials":249,"activeCount":95},[],{"trials":251,"activeCount":95},[],{"trials":253,"activeCount":95},[],{"trials":255,"activeCount":95},[],{"trials":257,"activeCount":135,"soonestReadout":40},[258],{"nctId":43,"briefTitle":44,"status":129,"phases":259,"primaryCompletion":40,"completion":131,"start":132,"enrollment":110,"conditions":260,"interventions":261},[86],[27],[45,90],{"trials":263,"activeCount":95},[],{"intervention":67,"totalTrials":265,"cells":266},9,{"EARLY_PHASE1":267,"PHASE1":269,"PHASE2":271,"PHASE3":273,"PHASE4":346,"NA":348},{"trials":268,"activeCount":95},[],{"trials":270,"activeCount":95},[],{"trials":272,"activeCount":95},[],{"trials":274,"activeCount":345,"soonestReadout":63},[275,283,293,299,309,315,325,331,338],{"nctId":69,"briefTitle":70,"status":129,"phases":276,"primaryCompletion":71,"completion":277,"start":278,"enrollment":279,"conditions":280,"interventions":281},[85],"2024-10-10","2022-05-01",870,[15],[67,282],"Clopidogrel",{"nctId":284,"briefTitle":285,"status":129,"phases":286,"primaryCompletion":287,"completion":288,"start":289,"enrollment":290,"conditions":291,"interventions":292},"NCT06561867","Ticagrelor Versus Cilostazol in Ischemic Stroke",[85],"2025-11-30","2025-12-20","2024-08-30",900,[15],[59,67],{"nctId":73,"briefTitle":74,"status":129,"phases":294,"primaryCompletion":75,"completion":295,"start":296,"enrollment":290,"conditions":297,"interventions":298},[85],"2024-12-30","2023-12-01",[15],[59,67],{"nctId":300,"briefTitle":301,"status":129,"phases":302,"primaryCompletion":303,"completion":304,"start":305,"enrollment":306,"conditions":307,"interventions":308},"NCT06202755","Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke",[85],"2025-06-12","2025-07-12","2024-03-30",580,[15],[59,67],{"nctId":61,"briefTitle":62,"status":129,"phases":310,"primaryCompletion":63,"completion":311,"start":312,"enrollment":290,"conditions":313,"interventions":314},[85],"2024-10-01","2022-02-09",[15],[59,67],{"nctId":316,"briefTitle":317,"status":129,"phases":318,"primaryCompletion":319,"completion":320,"start":321,"enrollment":290,"conditions":322,"interventions":323},"NCT06591377","Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA",[85],"2025-09-19","2025-10-01","2024-08-10",[15],[59,67,324,324],"Aspirin 75mg",{"nctId":65,"briefTitle":66,"status":129,"phases":326,"primaryCompletion":63,"completion":71,"start":327,"enrollment":279,"conditions":328,"interventions":329},[85],"2022-04-15",[15],[67,330],"Clopidogrel 75mg",{"nctId":332,"briefTitle":333,"status":118,"phases":334,"primaryCompletion":40,"completion":335,"start":122,"enrollment":279,"conditions":336,"interventions":337},"NCT06242132","Clopidogrel Versus Cilostazol in Ischemic Stroke",[85],"2024-08-01",[15],[282,67],{"nctId":339,"briefTitle":340,"status":118,"phases":341,"primaryCompletion":40,"completion":335,"start":342,"enrollment":306,"conditions":343,"interventions":344},"NCT06242145","Clopidogrel Versus Cilostazol in Large-vessel Ischemic Stroke",[85],"2023-01-01",[15],[282,67],7,{"trials":347,"activeCount":95},[],{"trials":349,"activeCount":95},[],{"intervention":59,"totalTrials":265,"cells":351},{"EARLY_PHASE1":352,"PHASE1":354,"PHASE2":356,"PHASE3":358,"PHASE4":413,"NA":415},{"trials":353,"activeCount":95},[],{"trials":355,"activeCount":95},[],{"trials":357,"activeCount":95},[],{"trials":359,"activeCount":345,"soonestReadout":58},[360,364,369,373,377,387,396,400,404],{"nctId":284,"briefTitle":285,"status":129,"phases":361,"primaryCompletion":287,"completion":288,"start":289,"enrollment":290,"conditions":362,"interventions":363},[85],[15],[59,67],{"nctId":56,"briefTitle":57,"status":129,"phases":365,"primaryCompletion":58,"completion":366,"start":278,"enrollment":290,"conditions":367,"interventions":368},[85],"2024-09-25",[15],[59,282],{"nctId":73,"briefTitle":74,"status":129,"phases":370,"primaryCompletion":75,"completion":295,"start":296,"enrollment":290,"conditions":371,"interventions":372},[85],[15],[59,67],{"nctId":300,"briefTitle":301,"status":129,"phases":374,"primaryCompletion":303,"completion":304,"start":305,"enrollment":306,"conditions":375,"interventions":376},[85],[15],[59,67],{"nctId":378,"briefTitle":379,"status":118,"phases":380,"primaryCompletion":381,"completion":382,"start":383,"enrollment":290,"conditions":384,"interventions":385},"NCT05553613","Ticagrelor Versus Clopidogrel in Ischemic Stroke",[85],"2023-10-01","2024-01-01","2022-10-01",[15],[386,282],"Ticagrelor 90 MG Oral",{"nctId":388,"briefTitle":389,"status":118,"phases":390,"primaryCompletion":391,"completion":392,"start":393,"enrollment":306,"conditions":394,"interventions":395},"NCT06120725","Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke",[85],"2023-09-01","2023-11-01","2021-09-01",[15],[59,282],{"nctId":61,"briefTitle":62,"status":129,"phases":397,"primaryCompletion":63,"completion":311,"start":312,"enrollment":290,"conditions":398,"interventions":399},[85],[15],[59,67],{"nctId":316,"briefTitle":317,"status":129,"phases":401,"primaryCompletion":319,"completion":320,"start":321,"enrollment":290,"conditions":402,"interventions":403},[85],[15],[59,67,324,324],{"nctId":405,"briefTitle":406,"status":129,"phases":407,"primaryCompletion":408,"completion":409,"start":49,"enrollment":290,"conditions":410,"interventions":411},"NCT06591338","Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA",[85],"2025-09-15","2025-10-10",[15],[59,282,412,412],"Aspirin 75 Mg Oral",{"trials":414,"activeCount":95},[],{"trials":416,"activeCount":95},[],{"intervention":282,"totalTrials":345,"cells":418},{"EARLY_PHASE1":419,"PHASE1":421,"PHASE2":423,"PHASE3":425,"PHASE4":455,"NA":457},{"trials":420,"activeCount":95},[],{"trials":422,"activeCount":95},[],{"trials":424,"activeCount":95},[],{"trials":426,"activeCount":91,"soonestReadout":58},[427,431,435,439,443,447,451],{"nctId":69,"briefTitle":70,"status":129,"phases":428,"primaryCompletion":71,"completion":277,"start":278,"enrollment":279,"conditions":429,"interventions":430},[85],[15],[67,282],{"nctId":56,"briefTitle":57,"status":129,"phases":432,"primaryCompletion":58,"completion":366,"start":278,"enrollment":290,"conditions":433,"interventions":434},[85],[15],[59,282],{"nctId":378,"briefTitle":379,"status":118,"phases":436,"primaryCompletion":381,"completion":382,"start":383,"enrollment":290,"conditions":437,"interventions":438},[85],[15],[386,282],{"nctId":388,"briefTitle":389,"status":118,"phases":440,"primaryCompletion":391,"completion":392,"start":393,"enrollment":306,"conditions":441,"interventions":442},[85],[15],[59,282],{"nctId":405,"briefTitle":406,"status":129,"phases":444,"primaryCompletion":408,"completion":409,"start":49,"enrollment":290,"conditions":445,"interventions":446},[85],[15],[59,282,412,412],{"nctId":332,"briefTitle":333,"status":118,"phases":448,"primaryCompletion":40,"completion":335,"start":122,"enrollment":279,"conditions":449,"interventions":450},[85],[15],[282,67],{"nctId":339,"briefTitle":340,"status":118,"phases":452,"primaryCompletion":40,"completion":335,"start":342,"enrollment":306,"conditions":453,"interventions":454},[85],[15],[282,67],{"trials":456,"activeCount":95},[],{"trials":458,"activeCount":95},[],{"intervention":460,"totalTrials":461,"cells":462},"Rosuvastatin 20mg",2,{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":469,"PHASE4":490,"NA":492},{"trials":464,"activeCount":95},[],{"trials":466,"activeCount":95},[],{"trials":468,"activeCount":95},[],{"trials":470,"activeCount":461,"soonestReadout":485},[471,481],{"nctId":472,"briefTitle":473,"status":129,"phases":474,"primaryCompletion":475,"completion":476,"start":477,"enrollment":110,"conditions":478,"interventions":479},"NCT06358313","Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Small Vessel Stroke",[85],"2026-05-10","2026-05-30","2024-04-10",[15],[480,460],"Atorvastatin 40mg",{"nctId":482,"briefTitle":483,"status":129,"phases":484,"primaryCompletion":485,"completion":320,"start":477,"enrollment":110,"conditions":486,"interventions":487},"NCT06360120","Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke",[85],"2025-09-10",[15],[488,460,489,489],"Atorvastatin 40 Mg Oral","Clopidogrel 75 Mg Oral",{"trials":491,"activeCount":95},[],{"trials":493,"activeCount":95},[],{"intervention":489,"totalTrials":461,"cells":495},{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":502,"PHASE4":520,"NA":522},{"trials":497,"activeCount":95},[],{"trials":499,"activeCount":95},[],{"trials":501,"activeCount":95},[],{"trials":503,"activeCount":461,"soonestReadout":485},[504,516],{"nctId":505,"briefTitle":506,"status":129,"phases":507,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":512,"interventions":513},"NCT07275749","Acetyl-leucine in Post-stroke Ataxia",[85],"2026-07-01","2026-07-20","2025-12-01",200,[15],[514,489,515],"Acetyl-Leucine","aspirin 100mg",{"nctId":482,"briefTitle":483,"status":129,"phases":517,"primaryCompletion":485,"completion":320,"start":477,"enrollment":110,"conditions":518,"interventions":519},[85],[15],[488,460,489,489],{"trials":521,"activeCount":95},[],{"trials":523,"activeCount":95},[],{"intervention":50,"totalTrials":461,"cells":525},{"EARLY_PHASE1":526,"PHASE1":528,"PHASE2":530,"PHASE3":532,"PHASE4":547,"NA":549},{"trials":527,"activeCount":95},[],{"trials":529,"activeCount":95},[],{"trials":531,"activeCount":95},[],{"trials":533,"activeCount":461,"soonestReadout":49},[534,542],{"nctId":47,"briefTitle":48,"status":129,"phases":535,"primaryCompletion":49,"completion":536,"start":537,"enrollment":511,"conditions":538,"interventions":540},[85],"2024-09-20","2021-08-01",[539],"Cerebral Venous Thrombosis",[50,541],"Rivaroxaban 20 MG Oral",{"nctId":52,"briefTitle":53,"status":129,"phases":543,"primaryCompletion":49,"completion":311,"start":537,"enrollment":511,"conditions":544,"interventions":546},[85],[545],"Cerebral Venous Sinus Thrombosis",[54,50],{"trials":548,"activeCount":95},[],{"trials":550,"activeCount":95},[],{"intervention":541,"totalTrials":461,"cells":552},{"EARLY_PHASE1":553,"PHASE1":555,"PHASE2":557,"PHASE3":559,"PHASE4":574,"NA":576},{"trials":554,"activeCount":95},[],{"trials":556,"activeCount":95},[],{"trials":558,"activeCount":95},[],{"trials":560,"activeCount":461,"soonestReadout":49},[561,565],{"nctId":47,"briefTitle":48,"status":129,"phases":562,"primaryCompletion":49,"completion":536,"start":537,"enrollment":511,"conditions":563,"interventions":564},[85],[539],[50,541],{"nctId":566,"briefTitle":567,"status":129,"phases":568,"primaryCompletion":569,"completion":570,"start":571,"enrollment":511,"conditions":572,"interventions":573},"NCT06551402","Dabigatran Versus Rivaroxaban in Cerebral Venous Thrombosis",[85],"2026-10-01","2026-11-01","2024-08-09",[545],[54,541],{"trials":575,"activeCount":95},[],{"trials":577,"activeCount":95},[],{"intervention":54,"totalTrials":461,"cells":579},{"EARLY_PHASE1":580,"PHASE1":582,"PHASE2":584,"PHASE3":586,"PHASE4":596,"NA":598},{"trials":581,"activeCount":95},[],{"trials":583,"activeCount":95},[],{"trials":585,"activeCount":95},[],{"trials":587,"activeCount":461,"soonestReadout":49},[588,592],{"nctId":566,"briefTitle":567,"status":129,"phases":589,"primaryCompletion":569,"completion":570,"start":571,"enrollment":511,"conditions":590,"interventions":591},[85],[545],[54,541],{"nctId":52,"briefTitle":53,"status":129,"phases":593,"primaryCompletion":49,"completion":311,"start":537,"enrollment":511,"conditions":594,"interventions":595},[85],[545],[54,50],{"trials":597,"activeCount":95},[],{"trials":599,"activeCount":95},[],{"intervention":324,"totalTrials":461,"cells":601},{"EARLY_PHASE1":602,"PHASE1":604,"PHASE2":606,"PHASE3":608,"PHASE4":625,"NA":627},{"trials":603,"activeCount":95},[],{"trials":605,"activeCount":95},[],{"trials":607,"activeCount":95},[],{"trials":609,"activeCount":135,"soonestReadout":319},[610,621],{"nctId":611,"briefTitle":612,"status":118,"phases":613,"primaryCompletion":614,"completion":614,"start":615,"enrollment":616,"conditions":617,"interventions":619},"NCT03884530","Ticagrelol Versus Aspirin in Ischemic Stroke",[85],"2020-09-30","2019-05-01",169,[618,15],"Acute Stroke",[620,324],"Ticagrelor (Brilique) 90",{"nctId":316,"briefTitle":317,"status":129,"phases":622,"primaryCompletion":319,"completion":320,"start":321,"enrollment":290,"conditions":623,"interventions":624},[85],[15],[59,67,324,324],{"trials":626,"activeCount":95},[],{"trials":628,"activeCount":95},[],{"intervention":480,"totalTrials":135,"cells":630},{"EARLY_PHASE1":631,"PHASE1":633,"PHASE2":635,"PHASE3":637,"PHASE4":643,"NA":645},{"trials":632,"activeCount":95},[],{"trials":634,"activeCount":95},[],{"trials":636,"activeCount":95},[],{"trials":638,"activeCount":135,"soonestReadout":475},[639],{"nctId":472,"briefTitle":473,"status":129,"phases":640,"primaryCompletion":475,"completion":476,"start":477,"enrollment":110,"conditions":641,"interventions":642},[85],[15],[480,460],{"trials":644,"activeCount":95},[],{"trials":646,"activeCount":95},[],{"intervention":514,"totalTrials":135,"cells":648},{"EARLY_PHASE1":649,"PHASE1":651,"PHASE2":653,"PHASE3":655,"PHASE4":661,"NA":663},{"trials":650,"activeCount":95},[],{"trials":652,"activeCount":95},[],{"trials":654,"activeCount":95},[],{"trials":656,"activeCount":135,"soonestReadout":508},[657],{"nctId":505,"briefTitle":506,"status":129,"phases":658,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":659,"interventions":660},[85],[15],[514,489,515],{"trials":662,"activeCount":95},[],{"trials":664,"activeCount":95},[],{"intervention":515,"totalTrials":135,"cells":666},{"EARLY_PHASE1":667,"PHASE1":669,"PHASE2":671,"PHASE3":673,"PHASE4":679,"NA":681},{"trials":668,"activeCount":95},[],{"trials":670,"activeCount":95},[],{"trials":672,"activeCount":95},[],{"trials":674,"activeCount":135,"soonestReadout":508},[675],{"nctId":505,"briefTitle":506,"status":129,"phases":676,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":677,"interventions":678},[85],[15],[514,489,515],{"trials":680,"activeCount":95},[],{"trials":682,"activeCount":95},[],{"intervention":488,"totalTrials":135,"cells":684},{"EARLY_PHASE1":685,"PHASE1":687,"PHASE2":689,"PHASE3":691,"PHASE4":697,"NA":699},{"trials":686,"activeCount":95},[],{"trials":688,"activeCount":95},[],{"trials":690,"activeCount":95},[],{"trials":692,"activeCount":135,"soonestReadout":485},[693],{"nctId":482,"briefTitle":483,"status":129,"phases":694,"primaryCompletion":485,"completion":320,"start":477,"enrollment":110,"conditions":695,"interventions":696},[85],[15],[488,460,489,489],{"trials":698,"activeCount":95},[],{"trials":700,"activeCount":95},[],{"intervention":330,"totalTrials":135,"cells":702},{"EARLY_PHASE1":703,"PHASE1":705,"PHASE2":707,"PHASE3":709,"PHASE4":715,"NA":717},{"trials":704,"activeCount":95},[],{"trials":706,"activeCount":95},[],{"trials":708,"activeCount":95},[],{"trials":710,"activeCount":135,"soonestReadout":63},[711],{"nctId":65,"briefTitle":66,"status":129,"phases":712,"primaryCompletion":63,"completion":71,"start":327,"enrollment":279,"conditions":713,"interventions":714},[85],[15],[67,330],{"trials":716,"activeCount":95},[],{"trials":718,"activeCount":95},[],{"intervention":412,"totalTrials":135,"cells":720},{"EARLY_PHASE1":721,"PHASE1":723,"PHASE2":725,"PHASE3":727,"PHASE4":733,"NA":735},{"trials":722,"activeCount":95},[],{"trials":724,"activeCount":95},[],{"trials":726,"activeCount":95},[],{"trials":728,"activeCount":135,"soonestReadout":408},[729],{"nctId":405,"briefTitle":406,"status":129,"phases":730,"primaryCompletion":408,"completion":409,"start":49,"enrollment":290,"conditions":731,"interventions":732},[85],[15],[59,282,412,412],{"trials":734,"activeCount":95},[],{"trials":736,"activeCount":95},[],{"intervention":738,"totalTrials":135,"cells":739},"Adductor Canal Block (ACB) Only",{"EARLY_PHASE1":740,"PHASE1":742,"PHASE2":744,"PHASE3":759,"PHASE4":761,"NA":763},{"trials":741,"activeCount":95},[],{"trials":743,"activeCount":95},[],{"trials":745,"activeCount":135,"soonestReadout":751},[746],{"nctId":747,"briefTitle":748,"status":749,"phases":750,"primaryCompletion":751,"completion":752,"start":753,"enrollment":754,"conditions":755,"interventions":758},"NCT07240402","Compare Morphine and Dexmedetomidine as Adjuvants to Bupivacaine in Ultrasound-guided ACB for Postoperative Analgesia After Knee Surgeries","NOT_YET_RECRUITING",[83,84],"2026-01-01","2026-02-01","2025-11-17",15,[756,757],"Postoperative Analgesia","Morphine and Dexmedetomidine",[738],{"trials":760,"activeCount":95},[],{"trials":762,"activeCount":95},[],{"trials":764,"activeCount":95},[],{"intervention":766,"totalTrials":135,"cells":767},"Sildenafil 25 MG",{"EARLY_PHASE1":768,"PHASE1":770,"PHASE2":772,"PHASE3":784,"PHASE4":786,"NA":788},{"trials":769,"activeCount":95},[],{"trials":771,"activeCount":95},[],{"trials":773,"activeCount":135,"soonestReadout":408},[774],{"nctId":775,"briefTitle":776,"status":129,"phases":777,"primaryCompletion":408,"completion":778,"start":49,"enrollment":779,"conditions":780,"interventions":782},"NCT07135037","Comparison Between Treatments of Oligohydramnios",[84],"2025-12-31",40,[781],"Oligohydramnios",[766,783],"L-Arginine, 1000 Mg Oral",{"trials":785,"activeCount":95},[],{"trials":787,"activeCount":95},[],{"trials":789,"activeCount":95},[],{"intervention":783,"totalTrials":135,"cells":791},{"EARLY_PHASE1":792,"PHASE1":794,"PHASE2":796,"PHASE3":802,"PHASE4":804,"NA":806},{"trials":793,"activeCount":95},[],{"trials":795,"activeCount":95},[],{"trials":797,"activeCount":135,"soonestReadout":408},[798],{"nctId":775,"briefTitle":776,"status":129,"phases":799,"primaryCompletion":408,"completion":778,"start":49,"enrollment":779,"conditions":800,"interventions":801},[84],[781],[766,783],{"trials":803,"activeCount":95},[],{"trials":805,"activeCount":95},[],{"trials":807,"activeCount":95},[],{"intervention":809,"totalTrials":135,"cells":810},"Group C",{"EARLY_PHASE1":811,"PHASE1":824,"PHASE2":826,"PHASE3":828,"PHASE4":830,"NA":832},{"trials":812,"activeCount":135,"soonestReadout":818},[813],{"nctId":814,"briefTitle":815,"status":816,"phases":817,"primaryCompletion":818,"completion":320,"start":819,"enrollment":11,"conditions":820,"interventions":823},"NCT06806007","Incentive Spirometer Training and Oropharyngeal Motor Training for Pulmonary Dysfunction in Spastic Diplegic Children","ACTIVE_NOT_RECRUITING",[82],"2025-08-30","2024-10-15",[821,822],"Pulmonary Dysfunction","Spastic Diaplegia",[809],{"trials":825,"activeCount":95},[],{"trials":827,"activeCount":95},[],{"trials":829,"activeCount":95},[],{"trials":831,"activeCount":95},[],{"trials":833,"activeCount":95},[],{"intervention":835,"totalTrials":135,"cells":836},"SGLT2 inhibitor",{"EARLY_PHASE1":837,"PHASE1":839,"PHASE2":841,"PHASE3":843,"PHASE4":845,"NA":847},{"trials":838,"activeCount":95},[],{"trials":840,"activeCount":95},[],{"trials":842,"activeCount":95},[],{"trials":844,"activeCount":95},[],{"trials":846,"activeCount":95},[],{"trials":848,"activeCount":135,"soonestReadout":853},[849],{"nctId":850,"briefTitle":851,"status":129,"phases":852,"primaryCompletion":853,"completion":853,"start":854,"enrollment":855,"conditions":856,"interventions":858},"NCT06585761","Effect of Sodium Glucose Co-tansporter 2 Inhibitors (SGLT2I) on Inflammatory and Oxidative Stress Markers Level in Heart Failure Patients",[],"2025-06-30","2024-02-15",60,[857],"Heart Failure",[835],{"intervention":860,"totalTrials":135,"cells":861},"only open flap debridement",{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":868,"PHASE4":870,"NA":872},{"trials":863,"activeCount":95},[],{"trials":865,"activeCount":95},[],{"trials":867,"activeCount":95},[],{"trials":869,"activeCount":95},[],{"trials":871,"activeCount":95},[],{"trials":873,"activeCount":135,"soonestReadout":878},[874],{"nctId":875,"briefTitle":876,"status":816,"phases":877,"primaryCompletion":878,"completion":879,"start":880,"enrollment":881,"conditions":882,"interventions":885},"NCT07358104","Efficacy of Camel Whey Protein and Camel Whey Protein Nanoparticles for Treating Intra-bony Periodontal Defects",[87],"2026-07-24","2026-08-04","2026-01-06",44,[883,884],"Periodontal Diseases","Periodontal Attachment Loss",[860,886,887,888],"scaffold material","CWP","CWP NPs",{"intervention":886,"totalTrials":135,"cells":890},{"EARLY_PHASE1":891,"PHASE1":893,"PHASE2":895,"PHASE3":897,"PHASE4":899,"NA":901},{"trials":892,"activeCount":95},[],{"trials":894,"activeCount":95},[],{"trials":896,"activeCount":95},[],{"trials":898,"activeCount":95},[],{"trials":900,"activeCount":95},[],{"trials":902,"activeCount":135,"soonestReadout":878},[903],{"nctId":875,"briefTitle":876,"status":816,"phases":904,"primaryCompletion":878,"completion":879,"start":880,"enrollment":881,"conditions":905,"interventions":906},[87],[883,884],[860,886,887,888],{"intervention":887,"totalTrials":135,"cells":908},{"EARLY_PHASE1":909,"PHASE1":911,"PHASE2":913,"PHASE3":915,"PHASE4":917,"NA":919},{"trials":910,"activeCount":95},[],{"trials":912,"activeCount":95},[],{"trials":914,"activeCount":95},[],{"trials":916,"activeCount":95},[],{"trials":918,"activeCount":95},[],{"trials":920,"activeCount":135,"soonestReadout":878},[921],{"nctId":875,"briefTitle":876,"status":816,"phases":922,"primaryCompletion":878,"completion":879,"start":880,"enrollment":881,"conditions":923,"interventions":924},[87],[883,884],[860,886,887,888],{"intervention":888,"totalTrials":135,"cells":926},{"EARLY_PHASE1":927,"PHASE1":929,"PHASE2":931,"PHASE3":933,"PHASE4":935,"NA":937},{"trials":928,"activeCount":95},[],{"trials":930,"activeCount":95},[],{"trials":932,"activeCount":95},[],{"trials":934,"activeCount":95},[],{"trials":936,"activeCount":95},[],{"trials":938,"activeCount":135,"soonestReadout":878},[939],{"nctId":875,"briefTitle":876,"status":816,"phases":940,"primaryCompletion":878,"completion":879,"start":880,"enrollment":881,"conditions":941,"interventions":942},[87],[883,884],[860,886,887,888],{"intervention":944,"totalTrials":135,"cells":945},"exosomes derived from human umbilical cord mesenchymal stem cells",{"EARLY_PHASE1":946,"PHASE1":948,"PHASE2":950,"PHASE3":952,"PHASE4":954,"NA":956},{"trials":947,"activeCount":95},[],{"trials":949,"activeCount":95},[],{"trials":951,"activeCount":95},[],{"trials":953,"activeCount":95},[],{"trials":955,"activeCount":95},[],{"trials":957,"activeCount":135,"soonestReadout":962},[958],{"nctId":959,"briefTitle":960,"status":129,"phases":961,"primaryCompletion":962,"completion":963,"start":964,"enrollment":965,"conditions":966,"interventions":969},"NCT07568184","A Randomized Trial of Intratympanic Drug Delivery: Evaluating the Efficacy and Safety of Dexamethasone-Loaded Exosomes Versus Standard Therapy in Acute Sensorineural Hearing Loss.",[87],"2027-04","2027-08","2026-04-03",30,[967,968],"Sensori-Neural Deafness","Exosomes",[944],{"intervention":971,"totalTrials":135,"cells":972},"physical therapy program for CP",{"EARLY_PHASE1":973,"PHASE1":975,"PHASE2":977,"PHASE3":979,"PHASE4":981,"NA":983},{"trials":974,"activeCount":95},[],{"trials":976,"activeCount":95},[],{"trials":978,"activeCount":95},[],{"trials":980,"activeCount":95},[],{"trials":982,"activeCount":95},[],{"trials":984,"activeCount":135,"soonestReadout":989},[985],{"nctId":986,"briefTitle":987,"status":749,"phases":988,"primaryCompletion":989,"completion":990,"start":991,"enrollment":992,"conditions":993,"interventions":995},"NCT06434246","Effect of Pully System on Hemiplegic Children",[87],"2025-08-20","2025-11-20","2025-02-20",32,[994],"Cerebral Palsy, Spastic",[971],{"intervention":997,"totalTrials":135,"cells":998},"Intracoronary tirofiban",{"EARLY_PHASE1":999,"PHASE1":1001,"PHASE2":1003,"PHASE3":1005,"PHASE4":1007,"NA":1009},{"trials":1000,"activeCount":95},[],{"trials":1002,"activeCount":95},[],{"trials":1004,"activeCount":95},[],{"trials":1006,"activeCount":95},[],{"trials":1008,"activeCount":95},[],{"trials":1010,"activeCount":135,"soonestReadout":320},[1011],{"nctId":1012,"briefTitle":1013,"status":129,"phases":1014,"primaryCompletion":320,"completion":320,"start":1015,"enrollment":855,"conditions":1016,"interventions":1021},"NCT06966674","No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track",[87],"2025-05-12",[1017,1018,1019,1020],"No-Reflow","STEMI","Intracoronary","Tirofiban",[997,1022],"Saline 0.9%",{"intervention":1022,"totalTrials":135,"cells":1024},{"EARLY_PHASE1":1025,"PHASE1":1027,"PHASE2":1029,"PHASE3":1031,"PHASE4":1033,"NA":1035},{"trials":1026,"activeCount":95},[],{"trials":1028,"activeCount":95},[],{"trials":1030,"activeCount":95},[],{"trials":1032,"activeCount":95},[],{"trials":1034,"activeCount":95},[],{"trials":1036,"activeCount":135,"soonestReadout":320},[1037],{"nctId":1012,"briefTitle":1013,"status":129,"phases":1038,"primaryCompletion":320,"completion":320,"start":1015,"enrollment":855,"conditions":1039,"interventions":1040},[87],[1017,1018,1019,1020],[997,1022],{"intervention":1042,"totalTrials":135,"cells":1043},"Intrathecal Dexmedetomidine",{"EARLY_PHASE1":1044,"PHASE1":1046,"PHASE2":1048,"PHASE3":1050,"PHASE4":1052,"NA":1054},{"trials":1045,"activeCount":95},[],{"trials":1047,"activeCount":95},[],{"trials":1049,"activeCount":95},[],{"trials":1051,"activeCount":95},[],{"trials":1053,"activeCount":95},[],{"trials":1055,"activeCount":135,"soonestReadout":237},[1056],{"nctId":1057,"briefTitle":1058,"status":129,"phases":1059,"primaryCompletion":237,"completion":237,"start":991,"enrollment":1060,"conditions":1061,"interventions":1064},"NCT06837844","Combined Intrathecal Dexmedetomidine and Adductor Canal Block for Analgesia After Total Knee Arthroplasty",[87],75,[1042,1062,32,1063],"Adductor Canal Block","Total Knee Arthroplasty",[1042,1062,1065],"Intrathecal Dexmedetomidine + Adductor Canal Block",{"intervention":1062,"totalTrials":135,"cells":1067},{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1072,"PHASE3":1074,"PHASE4":1076,"NA":1078},{"trials":1069,"activeCount":95},[],{"trials":1071,"activeCount":95},[],{"trials":1073,"activeCount":95},[],{"trials":1075,"activeCount":95},[],{"trials":1077,"activeCount":95},[],{"trials":1079,"activeCount":135,"soonestReadout":237},[1080],{"nctId":1057,"briefTitle":1058,"status":129,"phases":1081,"primaryCompletion":237,"completion":237,"start":991,"enrollment":1060,"conditions":1082,"interventions":1083},[87],[1042,1062,32,1063],[1042,1062,1065],{"intervention":1065,"totalTrials":135,"cells":1085},{"EARLY_PHASE1":1086,"PHASE1":1088,"PHASE2":1090,"PHASE3":1092,"PHASE4":1094,"NA":1096},{"trials":1087,"activeCount":95},[],{"trials":1089,"activeCount":95},[],{"trials":1091,"activeCount":95},[],{"trials":1093,"activeCount":95},[],{"trials":1095,"activeCount":95},[],{"trials":1097,"activeCount":135,"soonestReadout":237},[1098],{"nctId":1057,"briefTitle":1058,"status":129,"phases":1099,"primaryCompletion":237,"completion":237,"start":991,"enrollment":1060,"conditions":1100,"interventions":1101},[87],[1042,1062,32,1063],[1042,1062,1065],{"intervention":1103,"totalTrials":135,"cells":1104},"Traditional treatment",{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1109,"PHASE3":1111,"PHASE4":1113,"NA":1115},{"trials":1106,"activeCount":95},[],{"trials":1108,"activeCount":95},[],{"trials":1110,"activeCount":95},[],{"trials":1112,"activeCount":95},[],{"trials":1114,"activeCount":95},[],{"trials":1116,"activeCount":135,"soonestReadout":508},[1117],{"nctId":1118,"briefTitle":1119,"status":129,"phases":1120,"primaryCompletion":508,"completion":508,"start":1121,"enrollment":992,"conditions":1122,"interventions":1126},"NCT07352982","Transcutaneous Tibial Nerve Stimulation on Women With Primary Dysmenorrhea",[87],"2026-01-19",[1123,1124,1125],"Transcutaneous Tibial Nerve Stimulation","Women","Primary Dysmenorrhea",[1103],{"intervention":1128,"totalTrials":135,"cells":1129},"Demineralized Allogeneic Dentin Graft",{"EARLY_PHASE1":1130,"PHASE1":1132,"PHASE2":1134,"PHASE3":1136,"PHASE4":1138,"NA":1140},{"trials":1131,"activeCount":95},[],{"trials":1133,"activeCount":95},[],{"trials":1135,"activeCount":95},[],{"trials":1137,"activeCount":95},[],{"trials":1139,"activeCount":95},[],{"trials":1141,"activeCount":135,"soonestReadout":1146},[1142],{"nctId":1143,"briefTitle":1144,"status":129,"phases":1145,"primaryCompletion":1146,"completion":1147,"start":1148,"enrollment":1149,"conditions":1150,"interventions":1153},"NCT07242313","Comparison of Demineralized and Mineralized Dentin Grafts in Ridge Preservation",[87],"2026-08-01","2026-08-31","2025-10-21",45,[1151,1152],"Alveolar Ridge Preservation","Post Extraction Alveolar Bone Resorption",[1128,1154],"Mineralized Allogeneic Dentin Graft",{"intervention":1154,"totalTrials":135,"cells":1156},{"EARLY_PHASE1":1157,"PHASE1":1159,"PHASE2":1161,"PHASE3":1163,"PHASE4":1165,"NA":1167},{"trials":1158,"activeCount":95},[],{"trials":1160,"activeCount":95},[],{"trials":1162,"activeCount":95},[],{"trials":1164,"activeCount":95},[],{"trials":1166,"activeCount":95},[],{"trials":1168,"activeCount":135,"soonestReadout":1146},[1169],{"nctId":1143,"briefTitle":1144,"status":129,"phases":1170,"primaryCompletion":1146,"completion":1147,"start":1148,"enrollment":1149,"conditions":1171,"interventions":1172},[87],[1151,1152],[1128,1154],{"intervention":1174,"totalTrials":135,"cells":1175},"After successful revacularization, We will categorize patients into two groups : groups A (The patient's wound will be cleaned and irrigated with silver nanoparticle spray, then we will cover the woun",{"EARLY_PHASE1":1176,"PHASE1":1178,"PHASE2":1180,"PHASE3":1182,"PHASE4":1184,"NA":1186},{"trials":1177,"activeCount":95},[],{"trials":1179,"activeCount":95},[],{"trials":1181,"activeCount":95},[],{"trials":1183,"activeCount":95},[],{"trials":1185,"activeCount":95},[],{"trials":1187,"activeCount":135,"soonestReadout":409},[1188],{"nctId":1189,"briefTitle":1190,"status":1191,"phases":1192,"primaryCompletion":409,"completion":1193,"start":1194,"enrollment":1195,"conditions":1196,"interventions":1199},"NCT07147790","Comparative Study of Negative-Pressure Wound Therapy Integrated With Silver Nanoparticle Spray Versus Negative-Pressure Wound Therapy in Post-Revascularization Diabetic Foot Wound Management","ENROLLING_BY_INVITATION",[],"2025-12-10","2024-05-05",100,[1197,1198],"Ischemia Limb","Diabete Mellitus",[1174,1200],"Silver Nanoparticles Irrigant",{"intervention":1200,"totalTrials":135,"cells":1202},{"EARLY_PHASE1":1203,"PHASE1":1205,"PHASE2":1207,"PHASE3":1209,"PHASE4":1211,"NA":1213},{"trials":1204,"activeCount":95},[],{"trials":1206,"activeCount":95},[],{"trials":1208,"activeCount":95},[],{"trials":1210,"activeCount":95},[],{"trials":1212,"activeCount":95},[],{"trials":1214,"activeCount":135,"soonestReadout":409},[1215],{"nctId":1189,"briefTitle":1190,"status":1191,"phases":1216,"primaryCompletion":409,"completion":1193,"start":1194,"enrollment":1195,"conditions":1217,"interventions":1218},[],[1197,1198],[1174,1200],{"intervention":1220,"totalTrials":135,"cells":1221},"Vastus lateralis nerve block",{"EARLY_PHASE1":1222,"PHASE1":1224,"PHASE2":1226,"PHASE3":1228,"PHASE4":1230,"NA":1232},{"trials":1223,"activeCount":95},[],{"trials":1225,"activeCount":95},[],{"trials":1227,"activeCount":95},[],{"trials":1229,"activeCount":95},[],{"trials":1231,"activeCount":95},[],{"trials":1233,"activeCount":135,"soonestReadout":193},[1234],{"nctId":1235,"briefTitle":1236,"status":129,"phases":1237,"primaryCompletion":193,"completion":193,"start":1238,"enrollment":1239,"conditions":1240,"interventions":1244},"NCT06809842","Analgesic Efficacy of Blocking Nerve to Vastus Lateralis Muscle Versus Lateral Femoral Cutaneous Nerve After Knee Surgeries",[87],"2025-02-05",80,[32,1241,1242,1243],"Vastus Lateralis Nerve Block","Lateral Femoral Cutaneous Nerve Block","Knee Surgeries",[1220,1245],"Lateral femoral cutaneous nerve block",{"intervention":1245,"totalTrials":135,"cells":1247},{"EARLY_PHASE1":1248,"PHASE1":1250,"PHASE2":1252,"PHASE3":1254,"PHASE4":1256,"NA":1258},{"trials":1249,"activeCount":95},[],{"trials":1251,"activeCount":95},[],{"trials":1253,"activeCount":95},[],{"trials":1255,"activeCount":95},[],{"trials":1257,"activeCount":95},[],{"trials":1259,"activeCount":135,"soonestReadout":193},[1260],{"nctId":1235,"briefTitle":1236,"status":129,"phases":1261,"primaryCompletion":193,"completion":193,"start":1238,"enrollment":1239,"conditions":1262,"interventions":1263},[87],[32,1241,1242,1243],[1220,1245],{"intervention":1265,"totalTrials":135,"cells":1266},"Sacubitril\u002FValsartan",{"EARLY_PHASE1":1267,"PHASE1":1269,"PHASE2":1271,"PHASE3":1273,"PHASE4":1275,"NA":1277},{"trials":1268,"activeCount":95},[],{"trials":1270,"activeCount":95},[],{"trials":1272,"activeCount":95},[],{"trials":1274,"activeCount":95},[],{"trials":1276,"activeCount":95},[],{"trials":1278,"activeCount":135,"soonestReadout":752},[1279],{"nctId":1280,"briefTitle":1281,"status":129,"phases":1282,"primaryCompletion":752,"completion":752,"start":1283,"enrollment":1284,"conditions":1285,"interventions":1288},"NCT07192341","Sacubitril\u002FValsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction",[87],"2025-09-27",220,[1265,1286,857,1287],"Prosthetic Heart Valve","Reduced Ejection Fraction",[1265,1289],"Conventional anti-heart failure therapy",{"intervention":1289,"totalTrials":135,"cells":1291},{"EARLY_PHASE1":1292,"PHASE1":1294,"PHASE2":1296,"PHASE3":1298,"PHASE4":1300,"NA":1302},{"trials":1293,"activeCount":95},[],{"trials":1295,"activeCount":95},[],{"trials":1297,"activeCount":95},[],{"trials":1299,"activeCount":95},[],{"trials":1301,"activeCount":95},[],{"trials":1303,"activeCount":135,"soonestReadout":752},[1304],{"nctId":1280,"briefTitle":1281,"status":129,"phases":1305,"primaryCompletion":752,"completion":752,"start":1283,"enrollment":1284,"conditions":1306,"interventions":1307},[87],[1265,1286,857,1287],[1265,1289],{"intervention":1309,"totalTrials":135,"cells":1310},"Arm 2 Metformin Gel 1%",{"EARLY_PHASE1":1311,"PHASE1":1313,"PHASE2":1315,"PHASE3":1317,"PHASE4":1319,"NA":1321},{"trials":1312,"activeCount":95},[],{"trials":1314,"activeCount":95},[],{"trials":1316,"activeCount":95},[],{"trials":1318,"activeCount":95},[],{"trials":1320,"activeCount":95},[],{"trials":1322,"activeCount":135,"soonestReadout":1327},[1323],{"nctId":1324,"briefTitle":1325,"status":749,"phases":1326,"primaryCompletion":1327,"completion":1328,"start":1329,"enrollment":855,"conditions":1330,"interventions":1333},"NCT07215156","Metformin Versus Chlorhexidine Gel as Adjuncts to Scaling and Root Planing in Stage II Grade B Periodontitis",[87],"2026-04-10","2026-06-01","2025-10-06",[1331,1332],"Stage II, Grade B Periodontitis","Chronic Periodontitis",[1309,1334],"Arm 3 Chlorhexidine Gel 0.2%",{"intervention":1334,"totalTrials":135,"cells":1336},{"EARLY_PHASE1":1337,"PHASE1":1339,"PHASE2":1341,"PHASE3":1343,"PHASE4":1345,"NA":1347},{"trials":1338,"activeCount":95},[],{"trials":1340,"activeCount":95},[],{"trials":1342,"activeCount":95},[],{"trials":1344,"activeCount":95},[],{"trials":1346,"activeCount":95},[],{"trials":1348,"activeCount":135,"soonestReadout":1327},[1349],{"nctId":1324,"briefTitle":1325,"status":749,"phases":1350,"primaryCompletion":1327,"completion":1328,"start":1329,"enrollment":855,"conditions":1351,"interventions":1352},[87],[1331,1332],[1309,1334],{"intervention":1354,"totalTrials":461,"cells":1355},"intravenous dexmedetomidine",{"EARLY_PHASE1":1356,"PHASE1":1358,"PHASE2":1360,"PHASE3":1362,"PHASE4":1364,"NA":1389},{"trials":1357,"activeCount":95},[],{"trials":1359,"activeCount":95},[],{"trials":1361,"activeCount":95},[],{"trials":1363,"activeCount":95},[],{"trials":1365,"activeCount":95},[1366,1377],{"nctId":1367,"briefTitle":1368,"status":105,"phases":1369,"primaryCompletion":1370,"completion":1370,"start":1371,"enrollment":1372,"conditions":1373,"interventions":1375},"NCT06081933","Intranasal Dexmedetomidine Versus Intravenous Dexmedetomidine for Improving Quality of Endoscopic Sinus Surgery",[86],"2023-12-15","2022-12-20",54,[18,1374],"Functional Endoscopic Sinus",[1376,1354],"intranasal dexmedetomidine",{"nctId":1378,"briefTitle":1379,"status":118,"phases":1380,"primaryCompletion":1381,"completion":1381,"start":1382,"enrollment":855,"conditions":1383,"interventions":1386},"NCT05911776","Nasal Packing Versus Intravenous Dexmedetomidine in Turbinate Surgeries",[86],"2024-02-27","2023-06-30",[1384,18,1385],"Nasal Packing","Turbinate",[1387,1388],"Nasal packing Dexmedetomidine","Intravenous Dexmedetomidine",{"trials":1390,"activeCount":95},[],{"intervention":1392,"totalTrials":135,"cells":1393},"Warfarin 3 mg",{"EARLY_PHASE1":1394,"PHASE1":1396,"PHASE2":1398,"PHASE3":1400,"PHASE4":1402,"NA":1415},{"trials":1395,"activeCount":95},[],{"trials":1397,"activeCount":95},[],{"trials":1399,"activeCount":95},[],{"trials":1401,"activeCount":95},[],{"trials":1403,"activeCount":95},[1404],{"nctId":1405,"briefTitle":1406,"status":118,"phases":1407,"primaryCompletion":1408,"completion":1408,"start":1409,"enrollment":16,"conditions":1410,"interventions":1413},"NCT07571460","Clinical Application of Simcyp-Guided Warfarin Initiation Doses in Cirrhotic Patients With Portal Vein Thrombosis",[86],"2025-03-15","2024-03-15",[1411,1412],"Liver Cirrhosis","Portal Vein Thrombosis",[1392,1414],"Warfarin 2 mg",{"trials":1416,"activeCount":95},[],{"intervention":1414,"totalTrials":135,"cells":1418},{"EARLY_PHASE1":1419,"PHASE1":1421,"PHASE2":1423,"PHASE3":1425,"PHASE4":1427,"NA":1433},{"trials":1420,"activeCount":95},[],{"trials":1422,"activeCount":95},[],{"trials":1424,"activeCount":95},[],{"trials":1426,"activeCount":95},[],{"trials":1428,"activeCount":95},[1429],{"nctId":1405,"briefTitle":1406,"status":118,"phases":1430,"primaryCompletion":1408,"completion":1408,"start":1409,"enrollment":16,"conditions":1431,"interventions":1432},[86],[1411,1412],[1392,1414],{"trials":1434,"activeCount":95},[],{"intervention":1436,"totalTrials":135,"cells":1437},"Tadalafil 5 mg",{"EARLY_PHASE1":1438,"PHASE1":1440,"PHASE2":1442,"PHASE3":1444,"PHASE4":1446,"NA":1461},{"trials":1439,"activeCount":95},[],{"trials":1441,"activeCount":95},[],{"trials":1443,"activeCount":95},[],{"trials":1445,"activeCount":95},[],{"trials":1447,"activeCount":95},[1448],{"nctId":1449,"briefTitle":1450,"status":118,"phases":1451,"primaryCompletion":1452,"completion":1452,"start":1453,"enrollment":855,"conditions":1454,"interventions":1458},"NCT07563647","Association Between Diastolic Dysfunction and Erectile Dysfunction and the Effect of Tadalafil and SGLT2 Inhibitors on Them in Men With Metabolic Syndrome",[86],"2026-03-17","2025-05-05",[1455,1456,1457],"Erectile Dysfunction","Left Ventricular Diastolic Dysfunction","Metabolic Syndrome",[1436,1459,1460],"SGLT-2 inhibitor","Tadalafil plus SGLT2 inhibitors",{"trials":1462,"activeCount":95},[],{"intervention":1459,"totalTrials":135,"cells":1464},{"EARLY_PHASE1":1465,"PHASE1":1467,"PHASE2":1469,"PHASE3":1471,"PHASE4":1473,"NA":1479},{"trials":1466,"activeCount":95},[],{"trials":1468,"activeCount":95},[],{"trials":1470,"activeCount":95},[],{"trials":1472,"activeCount":95},[],{"trials":1474,"activeCount":95},[1475],{"nctId":1449,"briefTitle":1450,"status":118,"phases":1476,"primaryCompletion":1452,"completion":1452,"start":1453,"enrollment":855,"conditions":1477,"interventions":1478},[86],[1455,1456,1457],[1436,1459,1460],{"trials":1480,"activeCount":95},[],{"intervention":1460,"totalTrials":135,"cells":1482},{"EARLY_PHASE1":1483,"PHASE1":1485,"PHASE2":1487,"PHASE3":1489,"PHASE4":1491,"NA":1497},{"trials":1484,"activeCount":95},[],{"trials":1486,"activeCount":95},[],{"trials":1488,"activeCount":95},[],{"trials":1490,"activeCount":95},[],{"trials":1492,"activeCount":95},[1493],{"nctId":1449,"briefTitle":1450,"status":118,"phases":1494,"primaryCompletion":1452,"completion":1452,"start":1453,"enrollment":855,"conditions":1495,"interventions":1496},[86],[1455,1456,1457],[1436,1459,1460],{"trials":1498,"activeCount":95},[],{"intervention":1500,"totalTrials":135,"cells":1501},"Fascia lata membrane",{"EARLY_PHASE1":1502,"PHASE1":1504,"PHASE2":1506,"PHASE3":1508,"PHASE4":1510,"NA":1525},{"trials":1503,"activeCount":95},[],{"trials":1505,"activeCount":95},[],{"trials":1507,"activeCount":95},[],{"trials":1509,"activeCount":95},[],{"trials":1511,"activeCount":95},[1512],{"nctId":1513,"briefTitle":1514,"status":105,"phases":1515,"primaryCompletion":1516,"completion":1517,"start":1518,"enrollment":1519,"conditions":1520,"interventions":1522},"NCT06219473","Efficacy of Fascia Lata Allograft and Platelet Rich Fibrin on the Periodontal Phenotype Around Dental Implant",[86],"2025-01-01","2025-02-01","2024-02-01",24,[1521],"Allograft",[1500,1523,1524],"Platlet Rich fibrin membrane","subepithelial connective tissue graft",{"trials":1526,"activeCount":95},[],{"intervention":1523,"totalTrials":135,"cells":1528},{"EARLY_PHASE1":1529,"PHASE1":1531,"PHASE2":1533,"PHASE3":1535,"PHASE4":1537,"NA":1543},{"trials":1530,"activeCount":95},[],{"trials":1532,"activeCount":95},[],{"trials":1534,"activeCount":95},[],{"trials":1536,"activeCount":95},[],{"trials":1538,"activeCount":95},[1539],{"nctId":1513,"briefTitle":1514,"status":105,"phases":1540,"primaryCompletion":1516,"completion":1517,"start":1518,"enrollment":1519,"conditions":1541,"interventions":1542},[86],[1521],[1500,1523,1524],{"trials":1544,"activeCount":95},[],{"intervention":1524,"totalTrials":135,"cells":1546},{"EARLY_PHASE1":1547,"PHASE1":1549,"PHASE2":1551,"PHASE3":1553,"PHASE4":1555,"NA":1561},{"trials":1548,"activeCount":95},[],{"trials":1550,"activeCount":95},[],{"trials":1552,"activeCount":95},[],{"trials":1554,"activeCount":95},[],{"trials":1556,"activeCount":95},[1557],{"nctId":1513,"briefTitle":1514,"status":105,"phases":1558,"primaryCompletion":1516,"completion":1517,"start":1518,"enrollment":1519,"conditions":1559,"interventions":1560},[86],[1521],[1500,1523,1524],{"trials":1562,"activeCount":95},[],{"intervention":1564,"totalTrials":135,"cells":1565},"Mirabegron 100 mg",{"EARLY_PHASE1":1566,"PHASE1":1568,"PHASE2":1570,"PHASE3":1572,"PHASE4":1574,"NA":1591},{"trials":1567,"activeCount":95},[],{"trials":1569,"activeCount":95},[],{"trials":1571,"activeCount":95},[],{"trials":1573,"activeCount":95},[],{"trials":1575,"activeCount":95},[1576],{"nctId":1577,"briefTitle":1578,"status":118,"phases":1579,"primaryCompletion":1580,"completion":320,"start":40,"enrollment":1581,"conditions":1582,"interventions":1585},"NCT07533565","A Pilot Study of Mirabegron and Montelukast in Cirrhotic Patients",[86],"2025-07-01",78,[1583,1584],"Cirrhosis","Asthma",[1564,1586,1586,1587,1588,1589,1590],"Mirabegron 50mg","mirabegron 25 mg","Montelukast 10 mg","montelukast","montelukast 4 mg granule",{"trials":1592,"activeCount":95},[],{"intervention":1586,"totalTrials":135,"cells":1594},{"EARLY_PHASE1":1595,"PHASE1":1597,"PHASE2":1599,"PHASE3":1601,"PHASE4":1603,"NA":1609},{"trials":1596,"activeCount":95},[],{"trials":1598,"activeCount":95},[],{"trials":1600,"activeCount":95},[],{"trials":1602,"activeCount":95},[],{"trials":1604,"activeCount":95},[1605],{"nctId":1577,"briefTitle":1578,"status":118,"phases":1606,"primaryCompletion":1580,"completion":320,"start":40,"enrollment":1581,"conditions":1607,"interventions":1608},[86],[1583,1584],[1564,1586,1586,1587,1588,1589,1590],{"trials":1610,"activeCount":95},[],{"intervention":1587,"totalTrials":135,"cells":1612},{"EARLY_PHASE1":1613,"PHASE1":1615,"PHASE2":1617,"PHASE3":1619,"PHASE4":1621,"NA":1627},{"trials":1614,"activeCount":95},[],{"trials":1616,"activeCount":95},[],{"trials":1618,"activeCount":95},[],{"trials":1620,"activeCount":95},[],{"trials":1622,"activeCount":95},[1623],{"nctId":1577,"briefTitle":1578,"status":118,"phases":1624,"primaryCompletion":1580,"completion":320,"start":40,"enrollment":1581,"conditions":1625,"interventions":1626},[86],[1583,1584],[1564,1586,1586,1587,1588,1589,1590],{"trials":1628,"activeCount":95},[],{"intervention":1588,"totalTrials":135,"cells":1630},{"EARLY_PHASE1":1631,"PHASE1":1633,"PHASE2":1635,"PHASE3":1637,"PHASE4":1639,"NA":1645},{"trials":1632,"activeCount":95},[],{"trials":1634,"activeCount":95},[],{"trials":1636,"activeCount":95},[],{"trials":1638,"activeCount":95},[],{"trials":1640,"activeCount":95},[1641],{"nctId":1577,"briefTitle":1578,"status":118,"phases":1642,"primaryCompletion":1580,"completion":320,"start":40,"enrollment":1581,"conditions":1643,"interventions":1644},[86],[1583,1584],[1564,1586,1586,1587,1588,1589,1590],{"trials":1646,"activeCount":95},[],{"intervention":1589,"totalTrials":135,"cells":1648},{"EARLY_PHASE1":1649,"PHASE1":1651,"PHASE2":1653,"PHASE3":1655,"PHASE4":1657,"NA":1663},{"trials":1650,"activeCount":95},[],{"trials":1652,"activeCount":95},[],{"trials":1654,"activeCount":95},[],{"trials":1656,"activeCount":95},[],{"trials":1658,"activeCount":95},[1659],{"nctId":1577,"briefTitle":1578,"status":118,"phases":1660,"primaryCompletion":1580,"completion":320,"start":40,"enrollment":1581,"conditions":1661,"interventions":1662},[86],[1583,1584],[1564,1586,1586,1587,1588,1589,1590],{"trials":1664,"activeCount":95},[],{"intervention":1590,"totalTrials":135,"cells":1666},{"EARLY_PHASE1":1667,"PHASE1":1669,"PHASE2":1671,"PHASE3":1673,"PHASE4":1675,"NA":1681},{"trials":1668,"activeCount":95},[],{"trials":1670,"activeCount":95},[],{"trials":1672,"activeCount":95},[],{"trials":1674,"activeCount":95},[],{"trials":1676,"activeCount":95},[1677],{"nctId":1577,"briefTitle":1578,"status":118,"phases":1678,"primaryCompletion":1580,"completion":320,"start":40,"enrollment":1581,"conditions":1679,"interventions":1680},[86],[1583,1584],[1564,1586,1586,1587,1588,1589,1590],{"trials":1682,"activeCount":95},[],{"intervention":1684,"totalTrials":135,"cells":1685},"Vitamin E",{"EARLY_PHASE1":1686,"PHASE1":1688,"PHASE2":1690,"PHASE3":1692,"PHASE4":1694,"NA":1709},{"trials":1687,"activeCount":95},[],{"trials":1689,"activeCount":95},[],{"trials":1691,"activeCount":95},[],{"trials":1693,"activeCount":95},[],{"trials":1695,"activeCount":95},[1696],{"nctId":1697,"briefTitle":1698,"status":118,"phases":1699,"primaryCompletion":1700,"completion":1701,"start":1702,"enrollment":1703,"conditions":1704,"interventions":1706},"NCT04977661","Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) Patients",[86],"2020-05-20","2021-01-10","2020-02-01",102,[1705],"Nonalcoholic Steatohepatitis (NASH)",[1684,1707,1708],"Ursodeoxycholic acid","Pentoxifylline",{"trials":1710,"activeCount":95},[],{"intervention":1707,"totalTrials":135,"cells":1712},{"EARLY_PHASE1":1713,"PHASE1":1715,"PHASE2":1717,"PHASE3":1719,"PHASE4":1721,"NA":1727},{"trials":1714,"activeCount":95},[],{"trials":1716,"activeCount":95},[],{"trials":1718,"activeCount":95},[],{"trials":1720,"activeCount":95},[],{"trials":1722,"activeCount":95},[1723],{"nctId":1697,"briefTitle":1698,"status":118,"phases":1724,"primaryCompletion":1700,"completion":1701,"start":1702,"enrollment":1703,"conditions":1725,"interventions":1726},[86],[1705],[1684,1707,1708],{"trials":1728,"activeCount":95},[],{"intervention":1708,"totalTrials":135,"cells":1730},{"EARLY_PHASE1":1731,"PHASE1":1733,"PHASE2":1735,"PHASE3":1737,"PHASE4":1739,"NA":1745},{"trials":1732,"activeCount":95},[],{"trials":1734,"activeCount":95},[],{"trials":1736,"activeCount":95},[],{"trials":1738,"activeCount":95},[],{"trials":1740,"activeCount":95},[1741],{"nctId":1697,"briefTitle":1698,"status":118,"phases":1742,"primaryCompletion":1700,"completion":1701,"start":1702,"enrollment":1703,"conditions":1743,"interventions":1744},[86],[1705],[1684,1707,1708],{"trials":1746,"activeCount":95},[],{"intervention":1748,"totalTrials":135,"cells":1749},"Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone",{"EARLY_PHASE1":1750,"PHASE1":1752,"PHASE2":1754,"PHASE3":1756,"PHASE4":1758,"NA":1772},{"trials":1751,"activeCount":95},[],{"trials":1753,"activeCount":95},[],{"trials":1755,"activeCount":95},[],{"trials":1757,"activeCount":95},[],{"trials":1759,"activeCount":95},[1760],{"nctId":1761,"briefTitle":1762,"status":105,"phases":1763,"primaryCompletion":1764,"completion":1765,"start":1766,"enrollment":1767,"conditions":1768,"interventions":1770},"NCT04623385","Clinical Role of Testosterone and Dihydrotestosterone and Which of Them Should be Inhibited in COVID-19 Patients - A Double-edged Sword?",[86],"2020-12","2021-12","2020-11",1000,[1769],"Covid19",[1748,1771],"The standard therapy",{"trials":1773,"activeCount":95},[],{"intervention":1771,"totalTrials":135,"cells":1775},{"EARLY_PHASE1":1776,"PHASE1":1778,"PHASE2":1780,"PHASE3":1782,"PHASE4":1784,"NA":1790},{"trials":1777,"activeCount":95},[],{"trials":1779,"activeCount":95},[],{"trials":1781,"activeCount":95},[],{"trials":1783,"activeCount":95},[],{"trials":1785,"activeCount":95},[1786],{"nctId":1761,"briefTitle":1762,"status":105,"phases":1787,"primaryCompletion":1764,"completion":1765,"start":1766,"enrollment":1767,"conditions":1788,"interventions":1789},[86],[1769],[1748,1771],{"trials":1791,"activeCount":95},[],{"intervention":1793,"totalTrials":135,"cells":1794},"Nebivolol 5 mg",{"EARLY_PHASE1":1795,"PHASE1":1797,"PHASE2":1799,"PHASE3":1801,"PHASE4":1803,"NA":1817},{"trials":1796,"activeCount":95},[],{"trials":1798,"activeCount":95},[],{"trials":1800,"activeCount":95},[],{"trials":1802,"activeCount":95},[],{"trials":1804,"activeCount":95},[1805],{"nctId":1806,"briefTitle":1807,"status":118,"phases":1808,"primaryCompletion":1809,"completion":236,"start":1810,"enrollment":779,"conditions":1811,"interventions":1813},"NCT07397481","Clinical Application of Simcyp-Guided Doses of Antihypertensive Drugs in Cirrhotic Patients",[86],"2025-03-01","2024-03-01",[1411,1812],"Arterial Hypertension",[1793,1814,1815,1816],"Carvedilol 12.5 mg","Nebivolol 2.5 mg","Carvedilol 6.25 mg",{"trials":1818,"activeCount":95},[],{"intervention":1814,"totalTrials":135,"cells":1820},{"EARLY_PHASE1":1821,"PHASE1":1823,"PHASE2":1825,"PHASE3":1827,"PHASE4":1829,"NA":1835},{"trials":1822,"activeCount":95},[],{"trials":1824,"activeCount":95},[],{"trials":1826,"activeCount":95},[],{"trials":1828,"activeCount":95},[],{"trials":1830,"activeCount":95},[1831],{"nctId":1806,"briefTitle":1807,"status":118,"phases":1832,"primaryCompletion":1809,"completion":236,"start":1810,"enrollment":779,"conditions":1833,"interventions":1834},[86],[1411,1812],[1793,1814,1815,1816],{"trials":1836,"activeCount":95},[],{"intervention":1815,"totalTrials":135,"cells":1838},{"EARLY_PHASE1":1839,"PHASE1":1841,"PHASE2":1843,"PHASE3":1845,"PHASE4":1847,"NA":1853},{"trials":1840,"activeCount":95},[],{"trials":1842,"activeCount":95},[],{"trials":1844,"activeCount":95},[],{"trials":1846,"activeCount":95},[],{"trials":1848,"activeCount":95},[1849],{"nctId":1806,"briefTitle":1807,"status":118,"phases":1850,"primaryCompletion":1809,"completion":236,"start":1810,"enrollment":779,"conditions":1851,"interventions":1852},[86],[1411,1812],[1793,1814,1815,1816],{"trials":1854,"activeCount":95},[],{"intervention":1816,"totalTrials":135,"cells":1856},{"EARLY_PHASE1":1857,"PHASE1":1859,"PHASE2":1861,"PHASE3":1863,"PHASE4":1865,"NA":1871},{"trials":1858,"activeCount":95},[],{"trials":1860,"activeCount":95},[],{"trials":1862,"activeCount":95},[],{"trials":1864,"activeCount":95},[],{"trials":1866,"activeCount":95},[1867],{"nctId":1806,"briefTitle":1807,"status":118,"phases":1868,"primaryCompletion":1809,"completion":236,"start":1810,"enrollment":779,"conditions":1869,"interventions":1870},[86],[1411,1812],[1793,1814,1815,1816],{"trials":1872,"activeCount":95},[],{"intervention":1874,"totalTrials":135,"cells":1875},"Ketamine",{"EARLY_PHASE1":1876,"PHASE1":1878,"PHASE2":1880,"PHASE3":1882,"PHASE4":1884,"NA":1899},{"trials":1877,"activeCount":95},[],{"trials":1879,"activeCount":95},[],{"trials":1881,"activeCount":95},[],{"trials":1883,"activeCount":95},[],{"trials":1885,"activeCount":95},[1886],{"nctId":1887,"briefTitle":1888,"status":105,"phases":1889,"primaryCompletion":1890,"completion":1890,"start":1891,"enrollment":1060,"conditions":1892,"interventions":1897},"NCT05837000","Dexmedetomidine, Ketamine and Magnesium Sulphate in Caudal Block for Hypospadias Repair",[86],"2024-10-25","2023-05-15",[1893,18,1874,1894,1895,1896],"Preemptive Analgesia","Magnesium Sulphate","Hypospadias","Pediatrics",[18,1874,1898],"Magnesium sulphate",{"trials":1900,"activeCount":95},[],{"intervention":1898,"totalTrials":135,"cells":1902},{"EARLY_PHASE1":1903,"PHASE1":1905,"PHASE2":1907,"PHASE3":1909,"PHASE4":1911,"NA":1917},{"trials":1904,"activeCount":95},[],{"trials":1906,"activeCount":95},[],{"trials":1908,"activeCount":95},[],{"trials":1910,"activeCount":95},[],{"trials":1912,"activeCount":95},[1913],{"nctId":1887,"briefTitle":1888,"status":105,"phases":1914,"primaryCompletion":1890,"completion":1890,"start":1891,"enrollment":1060,"conditions":1915,"interventions":1916},[86],[1893,18,1874,1894,1895,1896],[18,1874,1898],{"trials":1918,"activeCount":95},[],{"intervention":1920,"totalTrials":135,"cells":1921},"Aerosolized 13 cis retinoic acid plus Vitamin D",{"EARLY_PHASE1":1922,"PHASE1":1924,"PHASE2":1926,"PHASE3":1928,"PHASE4":1930,"NA":1943},{"trials":1923,"activeCount":95},[],{"trials":1925,"activeCount":95},[],{"trials":1927,"activeCount":95},[],{"trials":1929,"activeCount":95},[],{"trials":1931,"activeCount":95},[1932],{"nctId":1933,"briefTitle":1934,"status":105,"phases":1935,"primaryCompletion":1765,"completion":1936,"start":1937,"enrollment":1938,"conditions":1939,"interventions":1941},"NCT05002530","Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.",[86],"2022-01","2021-11",10000,[1940],"Post COVID-19 Anosmia (Loss of Smell)",[1920,1942],"Aerosolized All trans retinoic acid plus Vitamin D",{"trials":1944,"activeCount":95},[],{"intervention":1942,"totalTrials":135,"cells":1946},{"EARLY_PHASE1":1947,"PHASE1":1949,"PHASE2":1951,"PHASE3":1953,"PHASE4":1955,"NA":1961},{"trials":1948,"activeCount":95},[],{"trials":1950,"activeCount":95},[],{"trials":1952,"activeCount":95},[],{"trials":1954,"activeCount":95},[],{"trials":1956,"activeCount":95},[1957],{"nctId":1933,"briefTitle":1934,"status":105,"phases":1958,"primaryCompletion":1765,"completion":1936,"start":1937,"enrollment":1938,"conditions":1959,"interventions":1960},[86],[1940],[1920,1942],{"trials":1962,"activeCount":95},[],{"intervention":1964,"totalTrials":135,"cells":1965},"Simvastatin 15 mg",{"EARLY_PHASE1":1966,"PHASE1":1968,"PHASE2":1970,"PHASE3":1972,"PHASE4":1974,"NA":1986},{"trials":1967,"activeCount":95},[],{"trials":1969,"activeCount":95},[],{"trials":1971,"activeCount":95},[],{"trials":1973,"activeCount":95},[],{"trials":1975,"activeCount":95},[1976],{"nctId":1977,"briefTitle":1978,"status":118,"phases":1979,"primaryCompletion":1408,"completion":1980,"start":1409,"enrollment":1981,"conditions":1982,"interventions":1984},"NCT07459972","Clinical Evaluation of Simcyp-Guided Simvastatin Dosing in Patients With Liver Cirrhosis",[86],"2025-06-15",22,[1411,1983],"Portal Hypertension Related to Cirrhosis",[1964,1985],"Simvastatin 5 mg",{"trials":1987,"activeCount":95},[],{"intervention":1985,"totalTrials":135,"cells":1989},{"EARLY_PHASE1":1990,"PHASE1":1992,"PHASE2":1994,"PHASE3":1996,"PHASE4":1998,"NA":2004},{"trials":1991,"activeCount":95},[],{"trials":1993,"activeCount":95},[],{"trials":1995,"activeCount":95},[],{"trials":1997,"activeCount":95},[],{"trials":1999,"activeCount":95},[2000],{"nctId":1977,"briefTitle":1978,"status":118,"phases":2001,"primaryCompletion":1408,"completion":1980,"start":1409,"enrollment":1981,"conditions":2002,"interventions":2003},[86],[1411,1983],[1964,1985],{"trials":2005,"activeCount":95},[],{"intervention":2007,"totalTrials":135,"cells":2008},"Budesonide intrapolyp",{"EARLY_PHASE1":2009,"PHASE1":2011,"PHASE2":2013,"PHASE3":2015,"PHASE4":2017,"NA":2033},{"trials":2010,"activeCount":95},[],{"trials":2012,"activeCount":95},[],{"trials":2014,"activeCount":95},[],{"trials":2016,"activeCount":95},[],{"trials":2018,"activeCount":95},[2019],{"nctId":2020,"briefTitle":2021,"status":105,"phases":2022,"primaryCompletion":2023,"completion":2024,"start":2025,"enrollment":2026,"conditions":2027,"interventions":2030},"NCT05474924","The Role of Budesonide Intrapolyp Injection in CRSwNP",[86],"2022-09-01","2022-12-01","2022-08-01",90,[2028,2029],"CRS","Polyp, Nasal",[2007,2031,2032],"Budesonide nasal wash","Prednisolone",{"trials":2034,"activeCount":95},[],{"intervention":2031,"totalTrials":135,"cells":2036},{"EARLY_PHASE1":2037,"PHASE1":2039,"PHASE2":2041,"PHASE3":2043,"PHASE4":2045,"NA":2051},{"trials":2038,"activeCount":95},[],{"trials":2040,"activeCount":95},[],{"trials":2042,"activeCount":95},[],{"trials":2044,"activeCount":95},[],{"trials":2046,"activeCount":95},[2047],{"nctId":2020,"briefTitle":2021,"status":105,"phases":2048,"primaryCompletion":2023,"completion":2024,"start":2025,"enrollment":2026,"conditions":2049,"interventions":2050},[86],[2028,2029],[2007,2031,2032],{"trials":2052,"activeCount":95},[],{"intervention":2032,"totalTrials":135,"cells":2054},{"EARLY_PHASE1":2055,"PHASE1":2057,"PHASE2":2059,"PHASE3":2061,"PHASE4":2063,"NA":2069},{"trials":2056,"activeCount":95},[],{"trials":2058,"activeCount":95},[],{"trials":2060,"activeCount":95},[],{"trials":2062,"activeCount":95},[],{"trials":2064,"activeCount":95},[2065],{"nctId":2020,"briefTitle":2021,"status":105,"phases":2066,"primaryCompletion":2023,"completion":2024,"start":2025,"enrollment":2026,"conditions":2067,"interventions":2068},[86],[2028,2029],[2007,2031,2032],{"trials":2070,"activeCount":95},[],{"intervention":2072,"totalTrials":135,"cells":2073},"Difluprednate Eye Drops",{"EARLY_PHASE1":2074,"PHASE1":2076,"PHASE2":2078,"PHASE3":2080,"PHASE4":2082,"NA":2094},{"trials":2075,"activeCount":95},[],{"trials":2077,"activeCount":95},[],{"trials":2079,"activeCount":95},[],{"trials":2081,"activeCount":95},[],{"trials":2083,"activeCount":95},[2084],{"nctId":2085,"briefTitle":2086,"status":105,"phases":2087,"primaryCompletion":2088,"completion":2088,"start":2089,"enrollment":2090,"conditions":2091,"interventions":2093},"NCT05649111","A Study of the Effect of Different Doses of Difluprednate Eye Drops on the Intraocular Pressure After Phacoemulsification",[86],"2023-02-01","2022-11-01",20,[2092],"Uveitis, Anterior",[2072],{"trials":2095,"activeCount":95},[],{"intervention":1376,"totalTrials":135,"cells":2097},{"EARLY_PHASE1":2098,"PHASE1":2100,"PHASE2":2102,"PHASE3":2104,"PHASE4":2106,"NA":2112},{"trials":2099,"activeCount":95},[],{"trials":2101,"activeCount":95},[],{"trials":2103,"activeCount":95},[],{"trials":2105,"activeCount":95},[],{"trials":2107,"activeCount":95},[2108],{"nctId":1367,"briefTitle":1368,"status":105,"phases":2109,"primaryCompletion":1370,"completion":1370,"start":1371,"enrollment":1372,"conditions":2110,"interventions":2111},[86],[18,1374],[1376,1354],{"trials":2113,"activeCount":95},[],{"intervention":2115,"totalTrials":135,"cells":2116},"Sitagliptin",{"EARLY_PHASE1":2117,"PHASE1":2119,"PHASE2":2121,"PHASE3":2123,"PHASE4":2125,"NA":2137},{"trials":2118,"activeCount":95},[],{"trials":2120,"activeCount":95},[],{"trials":2122,"activeCount":95},[],{"trials":2124,"activeCount":95},[],{"trials":2126,"activeCount":95},[2127],{"nctId":2128,"briefTitle":2129,"status":118,"phases":2130,"primaryCompletion":1580,"completion":320,"start":40,"enrollment":2131,"conditions":2132,"interventions":2134},"NCT07439536","Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis",[86],64,[2133],"Liver Cirrhosis With Diabetes",[2115,2115,2115,2115,2135,2136],"Duloxetine (60 mg) once daily","Duloxetine 30mg once daily",{"trials":2138,"activeCount":95},[],{"intervention":2135,"totalTrials":135,"cells":2140},{"EARLY_PHASE1":2141,"PHASE1":2143,"PHASE2":2145,"PHASE3":2147,"PHASE4":2149,"NA":2155},{"trials":2142,"activeCount":95},[],{"trials":2144,"activeCount":95},[],{"trials":2146,"activeCount":95},[],{"trials":2148,"activeCount":95},[],{"trials":2150,"activeCount":95},[2151],{"nctId":2128,"briefTitle":2129,"status":118,"phases":2152,"primaryCompletion":1580,"completion":320,"start":40,"enrollment":2131,"conditions":2153,"interventions":2154},[86],[2133],[2115,2115,2115,2115,2135,2136],{"trials":2156,"activeCount":95},[],{"intervention":2136,"totalTrials":135,"cells":2158},{"EARLY_PHASE1":2159,"PHASE1":2161,"PHASE2":2163,"PHASE3":2165,"PHASE4":2167,"NA":2173},{"trials":2160,"activeCount":95},[],{"trials":2162,"activeCount":95},[],{"trials":2164,"activeCount":95},[],{"trials":2166,"activeCount":95},[],{"trials":2168,"activeCount":95},[2169],{"nctId":2128,"briefTitle":2129,"status":118,"phases":2170,"primaryCompletion":1580,"completion":320,"start":40,"enrollment":2131,"conditions":2171,"interventions":2172},[86],[2133],[2115,2115,2115,2115,2135,2136],{"trials":2174,"activeCount":95},[],{"intervention":2176,"totalTrials":135,"cells":2177},"Minoxidil 5% topically and oral NAC 600 mg",{"EARLY_PHASE1":2178,"PHASE1":2180,"PHASE2":2182,"PHASE3":2184,"PHASE4":2186,"NA":2198},{"trials":2179,"activeCount":95},[],{"trials":2181,"activeCount":95},[],{"trials":2183,"activeCount":95},[],{"trials":2185,"activeCount":95},[],{"trials":2187,"activeCount":95},[2188],{"nctId":2189,"briefTitle":2190,"status":118,"phases":2191,"primaryCompletion":2192,"completion":2193,"start":2194,"enrollment":1195,"conditions":2195,"interventions":2197},"NCT04209803","N-Acetyl-Cysteine for Treatment of AGA in Men",[86],"2020-09-02","2020-10-01","2018-12-01",[2196],"Androgenetic Alopecia",[2176],{"trials":2199,"activeCount":95},[],{"intervention":2201,"totalTrials":135,"cells":2202},"Bupivacaine 0.25% Injectable Solution",{"EARLY_PHASE1":2203,"PHASE1":2205,"PHASE2":2207,"PHASE3":2209,"PHASE4":2211,"NA":2221},{"trials":2204,"activeCount":95},[],{"trials":2206,"activeCount":95},[],{"trials":2208,"activeCount":95},[],{"trials":2210,"activeCount":95},[],{"trials":2212,"activeCount":95},[2213],{"nctId":2214,"briefTitle":2215,"status":118,"phases":2216,"primaryCompletion":2217,"completion":2217,"start":2218,"enrollment":855,"conditions":2219,"interventions":2220},"NCT05892887","Analgesic Efficacy of Different Volumes in Erector Spinae Plane Block in Single Level Lumbar Spine Fixation",[86],"2023-09-20","2023-06-01",[32],[2201],{"trials":2222,"activeCount":95},[],{"intervention":1387,"totalTrials":135,"cells":2224},{"EARLY_PHASE1":2225,"PHASE1":2227,"PHASE2":2229,"PHASE3":2231,"PHASE4":2233,"NA":2239},{"trials":2226,"activeCount":95},[],{"trials":2228,"activeCount":95},[],{"trials":2230,"activeCount":95},[],{"trials":2232,"activeCount":95},[],{"trials":2234,"activeCount":95},[2235],{"nctId":1378,"briefTitle":1379,"status":118,"phases":2236,"primaryCompletion":1381,"completion":1381,"start":1382,"enrollment":855,"conditions":2237,"interventions":2238},[86],[1384,18,1385],[1387,1388],{"trials":2240,"activeCount":95},[],{"intervention":2242,"totalTrials":91,"cells":2243},"Aerosolized 13 cis retinoic acid",{"EARLY_PHASE1":2244,"PHASE1":2246,"PHASE2":2248,"PHASE3":2273,"PHASE4":2289,"NA":2291},{"trials":2245,"activeCount":95},[],{"trials":2247,"activeCount":95},[],{"trials":2249,"activeCount":95},[2250,2259],{"nctId":2251,"briefTitle":2252,"status":105,"phases":2253,"primaryCompletion":2254,"completion":1764,"start":2254,"enrollment":2255,"conditions":2256,"interventions":2257},"NCT04396067","Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment",[84],"2020-10",360,[30],[2242,2258],"Aerosolized All trans retinoic acid",{"nctId":2260,"briefTitle":2261,"status":105,"phases":2262,"primaryCompletion":2263,"completion":2264,"start":2265,"enrollment":2255,"conditions":2266,"interventions":2268},"NCT04730895","Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety.",[83,84],"2021-09","2023-12","2021-07",[2267],"Covid19 Vaccine",[2269,2242,2270,2271,2272],"Oral 13 cis retinoic acid","13 cis retinoic acid doses orally in combination with spike protein based vaccine","Aerosolized 13 cis retinoic acid in combination with spike protein based vaccine","Biological: spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine",{"trials":2274,"activeCount":95},[2275],{"nctId":2276,"briefTitle":2277,"status":105,"phases":2278,"primaryCompletion":2279,"completion":1937,"start":2280,"enrollment":2281,"conditions":2282,"interventions":2284},"NCT04353180","Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)",[85],"2021-10","2021-08",100000,[2283],"COVID19",[2285,2286,2287,2242,2288],"Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment","Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment","Isotretinoin (13 cis retinoic acid )","Standard treatment",{"trials":2290,"activeCount":95},[],{"trials":2292,"activeCount":95},[],{"intervention":2294,"totalTrials":461,"cells":2295},"Topiramate 50 MG",{"EARLY_PHASE1":2296,"PHASE1":2298,"PHASE2":2300,"PHASE3":2302,"PHASE4":2322,"NA":2324},{"trials":2297,"activeCount":95},[],{"trials":2299,"activeCount":95},[],{"trials":2301,"activeCount":95},[],{"trials":2303,"activeCount":95},[2304,2313],{"nctId":2305,"briefTitle":2306,"status":118,"phases":2307,"primaryCompletion":2308,"completion":2309,"start":278,"enrollment":110,"conditions":2310,"interventions":2311},"NCT06248931","Valproate Versus Topiramate in Migraine",[85],"2024-06-10","2024-06-30",[27],[2312,2294],"Valproic acid",{"nctId":2314,"briefTitle":2315,"status":118,"phases":2316,"primaryCompletion":2317,"completion":2318,"start":2319,"enrollment":110,"conditions":2320,"interventions":2321},"NCT06347497","Zonisamide Versus Topiramate in Migraine",[85],"2026-04-01","2026-04-30","2024-04-01",[112],[114,2294],{"trials":2323,"activeCount":95},[],{"trials":2325,"activeCount":95},[],{"intervention":114,"totalTrials":461,"cells":2327},{"EARLY_PHASE1":2328,"PHASE1":2330,"PHASE2":2332,"PHASE3":2334,"PHASE4":2344,"NA":2346},{"trials":2329,"activeCount":95},[],{"trials":2331,"activeCount":95},[],{"trials":2333,"activeCount":95},[],{"trials":2335,"activeCount":95},[2336,2340],{"nctId":103,"briefTitle":104,"status":105,"phases":2337,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":2338,"interventions":2339},[85],[112],[114,90],{"nctId":2314,"briefTitle":2315,"status":118,"phases":2341,"primaryCompletion":2317,"completion":2318,"start":2319,"enrollment":110,"conditions":2342,"interventions":2343},[85],[112],[114,2294],{"trials":2345,"activeCount":95},[],{"trials":2347,"activeCount":95},[],{"intervention":2349,"totalTrials":461,"cells":2350},"Lacosamide 50 MG Oral",{"EARLY_PHASE1":2351,"PHASE1":2353,"PHASE2":2355,"PHASE3":2357,"PHASE4":2379,"NA":2381},{"trials":2352,"activeCount":95},[],{"trials":2354,"activeCount":95},[],{"trials":2356,"activeCount":95},[],{"trials":2358,"activeCount":95},[2359,2369],{"nctId":2360,"briefTitle":2361,"status":118,"phases":2362,"primaryCompletion":2363,"completion":2364,"start":122,"enrollment":511,"conditions":2365,"interventions":2367},"NCT05632133","The Lacosamide's Effect on Calcitonin Gene-related Peptide in Migraine Patients",[85],"2023-08-09","2023-08-10",[2366,27],"Effect of Drug",[2349,2368],"Ibuprofen 400 mg",{"nctId":2370,"briefTitle":2371,"status":105,"phases":2372,"primaryCompletion":2373,"completion":2374,"start":1518,"enrollment":110,"conditions":2375,"interventions":2376},"NCT06243692","Lacosamide Versus Topiramate in Migraine",[85],"2025-02-02","2025-02-25",[27],[2377,2378],"Lacosamide 50 MG","Topiramate 50Mg Tab",{"trials":2380,"activeCount":95},[],{"trials":2382,"activeCount":95},[],{"intervention":2312,"totalTrials":135,"cells":2384},{"EARLY_PHASE1":2385,"PHASE1":2387,"PHASE2":2389,"PHASE3":2391,"PHASE4":2397,"NA":2399},{"trials":2386,"activeCount":95},[],{"trials":2388,"activeCount":95},[],{"trials":2390,"activeCount":95},[],{"trials":2392,"activeCount":95},[2393],{"nctId":2305,"briefTitle":2306,"status":118,"phases":2394,"primaryCompletion":2308,"completion":2309,"start":278,"enrollment":110,"conditions":2395,"interventions":2396},[85],[27],[2312,2294],{"trials":2398,"activeCount":95},[],{"trials":2400,"activeCount":95},[],{"intervention":2402,"totalTrials":135,"cells":2403},"Platelet rich fibrin",{"EARLY_PHASE1":2404,"PHASE1":2406,"PHASE2":2408,"PHASE3":2410,"PHASE4":2423,"NA":2425},{"trials":2405,"activeCount":95},[],{"trials":2407,"activeCount":95},[],{"trials":2409,"activeCount":95},[],{"trials":2411,"activeCount":95},[2412],{"nctId":2413,"briefTitle":2414,"status":118,"phases":2415,"primaryCompletion":2416,"completion":2417,"start":2418,"enrollment":779,"conditions":2419,"interventions":2421},"NCT07366762","Comparison Between Two Techniques in Treatment of Female Stress Urinary Incontinence",[85],"2025-05-01","2026-01-02","2024-07-10",[2420],"Female Stress Urinary Incontinence",[2422,2402],"Platelet Rich Plasma",{"trials":2424,"activeCount":95},[],{"trials":2426,"activeCount":95},[],{"intervention":620,"totalTrials":135,"cells":2428},{"EARLY_PHASE1":2429,"PHASE1":2431,"PHASE2":2433,"PHASE3":2435,"PHASE4":2441,"NA":2443},{"trials":2430,"activeCount":95},[],{"trials":2432,"activeCount":95},[],{"trials":2434,"activeCount":95},[],{"trials":2436,"activeCount":95},[2437],{"nctId":611,"briefTitle":612,"status":118,"phases":2438,"primaryCompletion":614,"completion":614,"start":615,"enrollment":616,"conditions":2439,"interventions":2440},[85],[618,15],[620,324],{"trials":2442,"activeCount":95},[],{"trials":2444,"activeCount":95},[],{"intervention":2446,"totalTrials":135,"cells":2447},"Citicoline 2000",{"EARLY_PHASE1":2448,"PHASE1":2450,"PHASE2":2452,"PHASE3":2454,"PHASE4":2466,"NA":2468},{"trials":2449,"activeCount":95},[],{"trials":2451,"activeCount":95},[],{"trials":2453,"activeCount":95},[],{"trials":2455,"activeCount":95},[2456],{"nctId":2457,"briefTitle":2458,"status":118,"phases":2459,"primaryCompletion":2460,"completion":2460,"start":2461,"enrollment":2462,"conditions":2463,"interventions":2464},"NCT06210646","Citicoline in Ischemic Stroke, a Randomized Trial",[85],"2024-06-29","2022-12-29",800,[15],[2446,2465],"citocoline 1000",{"trials":2467,"activeCount":95},[],{"trials":2469,"activeCount":95},[],{"intervention":2465,"totalTrials":135,"cells":2471},{"EARLY_PHASE1":2472,"PHASE1":2474,"PHASE2":2476,"PHASE3":2478,"PHASE4":2484,"NA":2486},{"trials":2473,"activeCount":95},[],{"trials":2475,"activeCount":95},[],{"trials":2477,"activeCount":95},[],{"trials":2479,"activeCount":95},[2480],{"nctId":2457,"briefTitle":2458,"status":118,"phases":2481,"primaryCompletion":2460,"completion":2460,"start":2461,"enrollment":2462,"conditions":2482,"interventions":2483},[85],[15],[2446,2465],{"trials":2485,"activeCount":95},[],{"trials":2487,"activeCount":95},[],{"intervention":2489,"totalTrials":135,"cells":2490},"Myoinositol",{"EARLY_PHASE1":2491,"PHASE1":2493,"PHASE2":2495,"PHASE3":2497,"PHASE4":2511,"NA":2513},{"trials":2492,"activeCount":95},[],{"trials":2494,"activeCount":95},[],{"trials":2496,"activeCount":95},[],{"trials":2498,"activeCount":95},[2499],{"nctId":2500,"briefTitle":2501,"status":118,"phases":2502,"primaryCompletion":475,"completion":2503,"start":2504,"enrollment":2505,"conditions":2506,"interventions":2509},"NCT07585396","Inositol in Letrozol Resistant PCOS Women",[84,85],"2026-05-11","2025-05-10",36,[2507,2508],"Polycystic Ovary Syndrome","Letrozol Resistant",[2489,2510],"Metformin",{"trials":2512,"activeCount":95},[],{"trials":2514,"activeCount":95},[],{"intervention":2510,"totalTrials":135,"cells":2516},{"EARLY_PHASE1":2517,"PHASE1":2519,"PHASE2":2521,"PHASE3":2523,"PHASE4":2529,"NA":2531},{"trials":2518,"activeCount":95},[],{"trials":2520,"activeCount":95},[],{"trials":2522,"activeCount":95},[],{"trials":2524,"activeCount":95},[2525],{"nctId":2500,"briefTitle":2501,"status":118,"phases":2526,"primaryCompletion":475,"completion":2503,"start":2504,"enrollment":2505,"conditions":2527,"interventions":2528},[84,85],[2507,2508],[2489,2510],{"trials":2530,"activeCount":95},[],{"trials":2532,"activeCount":95},[],{"intervention":2285,"totalTrials":135,"cells":2534},{"EARLY_PHASE1":2535,"PHASE1":2537,"PHASE2":2539,"PHASE3":2541,"PHASE4":2547,"NA":2549},{"trials":2536,"activeCount":95},[],{"trials":2538,"activeCount":95},[],{"trials":2540,"activeCount":95},[],{"trials":2542,"activeCount":95},[2543],{"nctId":2276,"briefTitle":2277,"status":105,"phases":2544,"primaryCompletion":2279,"completion":1937,"start":2280,"enrollment":2281,"conditions":2545,"interventions":2546},[85],[2283],[2285,2286,2287,2242,2288],{"trials":2548,"activeCount":95},[],{"trials":2550,"activeCount":95},[],{"intervention":2286,"totalTrials":135,"cells":2552},{"EARLY_PHASE1":2553,"PHASE1":2555,"PHASE2":2557,"PHASE3":2559,"PHASE4":2565,"NA":2567},{"trials":2554,"activeCount":95},[],{"trials":2556,"activeCount":95},[],{"trials":2558,"activeCount":95},[],{"trials":2560,"activeCount":95},[2561],{"nctId":2276,"briefTitle":2277,"status":105,"phases":2562,"primaryCompletion":2279,"completion":1937,"start":2280,"enrollment":2281,"conditions":2563,"interventions":2564},[85],[2283],[2285,2286,2287,2242,2288],{"trials":2566,"activeCount":95},[],{"trials":2568,"activeCount":95},[],{"intervention":2287,"totalTrials":135,"cells":2570},{"EARLY_PHASE1":2571,"PHASE1":2573,"PHASE2":2575,"PHASE3":2577,"PHASE4":2583,"NA":2585},{"trials":2572,"activeCount":95},[],{"trials":2574,"activeCount":95},[],{"trials":2576,"activeCount":95},[],{"trials":2578,"activeCount":95},[2579],{"nctId":2276,"briefTitle":2277,"status":105,"phases":2580,"primaryCompletion":2279,"completion":1937,"start":2280,"enrollment":2281,"conditions":2581,"interventions":2582},[85],[2283],[2285,2286,2287,2242,2288],{"trials":2584,"activeCount":95},[],{"trials":2586,"activeCount":95},[],{"intervention":2288,"totalTrials":135,"cells":2588},{"EARLY_PHASE1":2589,"PHASE1":2591,"PHASE2":2593,"PHASE3":2595,"PHASE4":2601,"NA":2603},{"trials":2590,"activeCount":95},[],{"trials":2592,"activeCount":95},[],{"trials":2594,"activeCount":95},[],{"trials":2596,"activeCount":95},[2597],{"nctId":2276,"briefTitle":2277,"status":105,"phases":2598,"primaryCompletion":2279,"completion":1937,"start":2280,"enrollment":2281,"conditions":2599,"interventions":2600},[85],[2283],[2285,2286,2287,2242,2288],{"trials":2602,"activeCount":95},[],{"trials":2604,"activeCount":95},[],{"intervention":2606,"totalTrials":135,"cells":2607},"Budesonide",{"EARLY_PHASE1":2608,"PHASE1":2610,"PHASE2":2612,"PHASE3":2614,"PHASE4":2627,"NA":2629},{"trials":2609,"activeCount":95},[],{"trials":2611,"activeCount":95},[],{"trials":2613,"activeCount":95},[],{"trials":2615,"activeCount":95},[2616],{"nctId":2617,"briefTitle":2618,"status":118,"phases":2619,"primaryCompletion":2088,"completion":2088,"start":2620,"enrollment":2621,"conditions":2622,"interventions":2624},"NCT05931744","The Role of Budesonide Intrapolyp Injection in the Management of Type 2 Chronic Rhinosinusitis",[84,85],"2021-05-01",120,[2623],"Chronic Rhinosinusitis With Nasal Polyps",[2606,2625,2626],"Prednisone","Saline",{"trials":2628,"activeCount":95},[],{"trials":2630,"activeCount":95},[],{"intervention":2625,"totalTrials":135,"cells":2632},{"EARLY_PHASE1":2633,"PHASE1":2635,"PHASE2":2637,"PHASE3":2639,"PHASE4":2645,"NA":2647},{"trials":2634,"activeCount":95},[],{"trials":2636,"activeCount":95},[],{"trials":2638,"activeCount":95},[],{"trials":2640,"activeCount":95},[2641],{"nctId":2617,"briefTitle":2618,"status":118,"phases":2642,"primaryCompletion":2088,"completion":2088,"start":2620,"enrollment":2621,"conditions":2643,"interventions":2644},[84,85],[2623],[2606,2625,2626],{"trials":2646,"activeCount":95},[],{"trials":2648,"activeCount":95},[],{"intervention":2626,"totalTrials":135,"cells":2650},{"EARLY_PHASE1":2651,"PHASE1":2653,"PHASE2":2655,"PHASE3":2657,"PHASE4":2663,"NA":2665},{"trials":2652,"activeCount":95},[],{"trials":2654,"activeCount":95},[],{"trials":2656,"activeCount":95},[],{"trials":2658,"activeCount":95},[2659],{"nctId":2617,"briefTitle":2618,"status":118,"phases":2660,"primaryCompletion":2088,"completion":2088,"start":2620,"enrollment":2621,"conditions":2661,"interventions":2662},[84,85],[2623],[2606,2625,2626],{"trials":2664,"activeCount":95},[],{"trials":2666,"activeCount":95},[],{"intervention":2368,"totalTrials":135,"cells":2668},{"EARLY_PHASE1":2669,"PHASE1":2671,"PHASE2":2673,"PHASE3":2675,"PHASE4":2681,"NA":2683},{"trials":2670,"activeCount":95},[],{"trials":2672,"activeCount":95},[],{"trials":2674,"activeCount":95},[],{"trials":2676,"activeCount":95},[2677],{"nctId":2360,"briefTitle":2361,"status":118,"phases":2678,"primaryCompletion":2363,"completion":2364,"start":122,"enrollment":511,"conditions":2679,"interventions":2680},[85],[2366,27],[2349,2368],{"trials":2682,"activeCount":95},[],{"trials":2684,"activeCount":95},[],{"intervention":2378,"totalTrials":135,"cells":2686},{"EARLY_PHASE1":2687,"PHASE1":2689,"PHASE2":2691,"PHASE3":2693,"PHASE4":2699,"NA":2701},{"trials":2688,"activeCount":95},[],{"trials":2690,"activeCount":95},[],{"trials":2692,"activeCount":95},[],{"trials":2694,"activeCount":95},[2695],{"nctId":2370,"briefTitle":2371,"status":105,"phases":2696,"primaryCompletion":2373,"completion":2374,"start":1518,"enrollment":110,"conditions":2697,"interventions":2698},[85],[27],[2377,2378],{"trials":2700,"activeCount":95},[],{"trials":2702,"activeCount":95},[],{"intervention":125,"totalTrials":135,"cells":2704},{"EARLY_PHASE1":2705,"PHASE1":2707,"PHASE2":2709,"PHASE3":2711,"PHASE4":2717,"NA":2719},{"trials":2706,"activeCount":95},[],{"trials":2708,"activeCount":95},[],{"trials":2710,"activeCount":95},[],{"trials":2712,"activeCount":95},[2713],{"nctId":116,"briefTitle":117,"status":118,"phases":2714,"primaryCompletion":120,"completion":121,"start":122,"enrollment":110,"conditions":2715,"interventions":2716},[85],[27],[125,90],{"trials":2718,"activeCount":95},[],{"trials":2720,"activeCount":95},[],{"intervention":2722,"totalTrials":135,"cells":2723},"Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole",{"EARLY_PHASE1":2724,"PHASE1":2726,"PHASE2":2728,"PHASE3":2739,"PHASE4":2741,"NA":2743},{"trials":2725,"activeCount":95},[],{"trials":2727,"activeCount":95},[],{"trials":2729,"activeCount":95},[2730],{"nctId":2731,"briefTitle":2732,"status":105,"phases":2733,"primaryCompletion":2734,"completion":2734,"start":2735,"enrollment":1149,"conditions":2736,"interventions":2737},"NCT04577378","Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19",[84],"2020-11-20","2020-10-20",[1769],[2722,2738],"Drug: Isotretinoin",{"trials":2740,"activeCount":95},[],{"trials":2742,"activeCount":95},[],{"trials":2744,"activeCount":95},[],{"intervention":2738,"totalTrials":135,"cells":2746},{"EARLY_PHASE1":2747,"PHASE1":2749,"PHASE2":2751,"PHASE3":2757,"PHASE4":2759,"NA":2761},{"trials":2748,"activeCount":95},[],{"trials":2750,"activeCount":95},[],{"trials":2752,"activeCount":95},[2753],{"nctId":2731,"briefTitle":2732,"status":105,"phases":2754,"primaryCompletion":2734,"completion":2734,"start":2735,"enrollment":1149,"conditions":2755,"interventions":2756},[84],[1769],[2722,2738],{"trials":2758,"activeCount":95},[],{"trials":2760,"activeCount":95},[],{"trials":2762,"activeCount":95},[],{"intervention":2258,"totalTrials":135,"cells":2764},{"EARLY_PHASE1":2765,"PHASE1":2767,"PHASE2":2769,"PHASE3":2775,"PHASE4":2777,"NA":2779},{"trials":2766,"activeCount":95},[],{"trials":2768,"activeCount":95},[],{"trials":2770,"activeCount":95},[2771],{"nctId":2251,"briefTitle":2252,"status":105,"phases":2772,"primaryCompletion":2254,"completion":1764,"start":2254,"enrollment":2255,"conditions":2773,"interventions":2774},[84],[30],[2242,2258],{"trials":2776,"activeCount":95},[],{"trials":2778,"activeCount":95},[],{"trials":2780,"activeCount":95},[],{"intervention":2782,"totalTrials":135,"cells":2783},"13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for",{"EARLY_PHASE1":2784,"PHASE1":2786,"PHASE2":2788,"PHASE3":2803,"PHASE4":2805,"NA":2807},{"trials":2785,"activeCount":95},[],{"trials":2787,"activeCount":95},[],{"trials":2789,"activeCount":95},[2790],{"nctId":2791,"briefTitle":2792,"status":105,"phases":2793,"primaryCompletion":2794,"completion":2794,"start":1765,"enrollment":2795,"conditions":2796,"interventions":2798},"NCT05077813","Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for Treating Patients With Multidrug-resistant TB and Patient With Both Multidrug-resistant TB and COVID-19",[84],"2022-02",250,[2797],"Tuberculosis",[2782,2799,2800,2801,2802],"9 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for","All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D for","All trans retinoic acid, Minocycline, Chicroic Acid and Vitamin D For","13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D For",{"trials":2804,"activeCount":95},[],{"trials":2806,"activeCount":95},[],{"trials":2808,"activeCount":95},[],{"intervention":2799,"totalTrials":135,"cells":2810},{"EARLY_PHASE1":2811,"PHASE1":2813,"PHASE2":2815,"PHASE3":2821,"PHASE4":2823,"NA":2825},{"trials":2812,"activeCount":95},[],{"trials":2814,"activeCount":95},[],{"trials":2816,"activeCount":95},[2817],{"nctId":2791,"briefTitle":2792,"status":105,"phases":2818,"primaryCompletion":2794,"completion":2794,"start":1765,"enrollment":2795,"conditions":2819,"interventions":2820},[84],[2797],[2782,2799,2800,2801,2802],{"trials":2822,"activeCount":95},[],{"trials":2824,"activeCount":95},[],{"trials":2826,"activeCount":95},[],{"intervention":2800,"totalTrials":135,"cells":2828},{"EARLY_PHASE1":2829,"PHASE1":2831,"PHASE2":2833,"PHASE3":2839,"PHASE4":2841,"NA":2843},{"trials":2830,"activeCount":95},[],{"trials":2832,"activeCount":95},[],{"trials":2834,"activeCount":95},[2835],{"nctId":2791,"briefTitle":2792,"status":105,"phases":2836,"primaryCompletion":2794,"completion":2794,"start":1765,"enrollment":2795,"conditions":2837,"interventions":2838},[84],[2797],[2782,2799,2800,2801,2802],{"trials":2840,"activeCount":95},[],{"trials":2842,"activeCount":95},[],{"trials":2844,"activeCount":95},[],{"intervention":2801,"totalTrials":135,"cells":2846},{"EARLY_PHASE1":2847,"PHASE1":2849,"PHASE2":2851,"PHASE3":2857,"PHASE4":2859,"NA":2861},{"trials":2848,"activeCount":95},[],{"trials":2850,"activeCount":95},[],{"trials":2852,"activeCount":95},[2853],{"nctId":2791,"briefTitle":2792,"status":105,"phases":2854,"primaryCompletion":2794,"completion":2794,"start":1765,"enrollment":2795,"conditions":2855,"interventions":2856},[84],[2797],[2782,2799,2800,2801,2802],{"trials":2858,"activeCount":95},[],{"trials":2860,"activeCount":95},[],{"trials":2862,"activeCount":95},[],{"intervention":2864,"totalTrials":135,"cells":2865},"Drug: Isotretinoin plus Tamoxifen",{"EARLY_PHASE1":2866,"PHASE1":2868,"PHASE2":2870,"PHASE3":2879,"PHASE4":2881,"NA":2883},{"trials":2867,"activeCount":95},[],{"trials":2869,"activeCount":95},[],{"trials":2871,"activeCount":95},[2872],{"nctId":2873,"briefTitle":2874,"status":105,"phases":2875,"primaryCompletion":2279,"completion":1765,"start":2263,"enrollment":239,"conditions":2876,"interventions":2877},"NCT04389580","Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus",[84],[30],[2864,2878],"Aerosolized Isotretinoin plus Tamoxifen",{"trials":2880,"activeCount":95},[],{"trials":2882,"activeCount":95},[],{"trials":2884,"activeCount":95},[],{"intervention":2878,"totalTrials":135,"cells":2886},{"EARLY_PHASE1":2887,"PHASE1":2889,"PHASE2":2891,"PHASE3":2897,"PHASE4":2899,"NA":2901},{"trials":2888,"activeCount":95},[],{"trials":2890,"activeCount":95},[],{"trials":2892,"activeCount":95},[2893],{"nctId":2873,"briefTitle":2874,"status":105,"phases":2894,"primaryCompletion":2279,"completion":1765,"start":2263,"enrollment":239,"conditions":2895,"interventions":2896},[84],[30],[2864,2878],{"trials":2898,"activeCount":95},[],{"trials":2900,"activeCount":95},[],{"trials":2902,"activeCount":95},[],{"intervention":2904,"totalTrials":135,"cells":2905},"Aerosolized All-Trans Retinoic acid plus oral Tamoxifen",{"EARLY_PHASE1":2906,"PHASE1":2908,"PHASE2":2910,"PHASE3":2919,"PHASE4":2921,"NA":2923},{"trials":2907,"activeCount":95},[],{"trials":2909,"activeCount":95},[],{"trials":2911,"activeCount":95},[2912],{"nctId":2913,"briefTitle":2914,"status":105,"phases":2915,"primaryCompletion":1764,"completion":1764,"start":1766,"enrollment":239,"conditions":2916,"interventions":2918},"NCT04568096","Combination of Chemopreventive Agents (All- Trans Retinoic Acid and Tamoxifen) as Potential Treatment for the Lung Complication of COVID-19",[84],[2917],"the Lung Complication of COVID-19",[2904],{"trials":2920,"activeCount":95},[],{"trials":2922,"activeCount":95},[],{"trials":2924,"activeCount":95},[],{"intervention":2269,"totalTrials":135,"cells":2926},{"EARLY_PHASE1":2927,"PHASE1":2929,"PHASE2":2931,"PHASE3":2937,"PHASE4":2939,"NA":2941},{"trials":2928,"activeCount":95},[],{"trials":2930,"activeCount":95},[],{"trials":2932,"activeCount":95},[2933],{"nctId":2260,"briefTitle":2261,"status":105,"phases":2934,"primaryCompletion":2263,"completion":2264,"start":2265,"enrollment":2255,"conditions":2935,"interventions":2936},[83,84],[2267],[2269,2242,2270,2271,2272],{"trials":2938,"activeCount":95},[],{"trials":2940,"activeCount":95},[],{"trials":2942,"activeCount":95},[],{"intervention":2270,"totalTrials":135,"cells":2944},{"EARLY_PHASE1":2945,"PHASE1":2947,"PHASE2":2949,"PHASE3":2955,"PHASE4":2957,"NA":2959},{"trials":2946,"activeCount":95},[],{"trials":2948,"activeCount":95},[],{"trials":2950,"activeCount":95},[2951],{"nctId":2260,"briefTitle":2261,"status":105,"phases":2952,"primaryCompletion":2263,"completion":2264,"start":2265,"enrollment":2255,"conditions":2953,"interventions":2954},[83,84],[2267],[2269,2242,2270,2271,2272],{"trials":2956,"activeCount":95},[],{"trials":2958,"activeCount":95},[],{"trials":2960,"activeCount":95},[],{"intervention":2271,"totalTrials":135,"cells":2962},{"EARLY_PHASE1":2963,"PHASE1":2965,"PHASE2":2967,"PHASE3":2973,"PHASE4":2975,"NA":2977},{"trials":2964,"activeCount":95},[],{"trials":2966,"activeCount":95},[],{"trials":2968,"activeCount":95},[2969],{"nctId":2260,"briefTitle":2261,"status":105,"phases":2970,"primaryCompletion":2263,"completion":2264,"start":2265,"enrollment":2255,"conditions":2971,"interventions":2972},[83,84],[2267],[2269,2242,2270,2271,2272],{"trials":2974,"activeCount":95},[],{"trials":2976,"activeCount":95},[],{"trials":2978,"activeCount":95},[],{"intervention":2272,"totalTrials":135,"cells":2980},{"EARLY_PHASE1":2981,"PHASE1":2983,"PHASE2":2985,"PHASE3":2991,"PHASE4":2993,"NA":2995},{"trials":2982,"activeCount":95},[],{"trials":2984,"activeCount":95},[],{"trials":2986,"activeCount":95},[2987],{"nctId":2260,"briefTitle":2261,"status":105,"phases":2988,"primaryCompletion":2263,"completion":2264,"start":2265,"enrollment":2255,"conditions":2989,"interventions":2990},[83,84],[2267],[2269,2242,2270,2271,2272],{"trials":2992,"activeCount":95},[],{"trials":2994,"activeCount":95},[],{"trials":2996,"activeCount":95},[],{"intervention":2998,"totalTrials":135,"cells":2999},"Topical dexmedetomidine",{"EARLY_PHASE1":3000,"PHASE1":3002,"PHASE2":3004,"PHASE3":3019,"PHASE4":3021,"NA":3023},{"trials":3001,"activeCount":95},[],{"trials":3003,"activeCount":95},[],{"trials":3005,"activeCount":95},[3006],{"nctId":3007,"briefTitle":3008,"status":105,"phases":3009,"primaryCompletion":3010,"completion":3010,"start":3011,"enrollment":3012,"conditions":3013,"interventions":3017},"NCT05692167","Dexmedetomidine in Topical Versus Peribulbar Anesthesia for Cataract Surgery",[84],"2023-10-15","2023-07-15",94,[18,3014,3015,3016],"Cataract Surgery","Peribulbar","Anesthesia",[2998,3018],"Reginal dexmedetomidine",{"trials":3020,"activeCount":95},[],{"trials":3022,"activeCount":95},[],{"trials":3024,"activeCount":95},[],{"intervention":3018,"totalTrials":135,"cells":3026},{"EARLY_PHASE1":3027,"PHASE1":3029,"PHASE2":3031,"PHASE3":3037,"PHASE4":3039,"NA":3041},{"trials":3028,"activeCount":95},[],{"trials":3030,"activeCount":95},[],{"trials":3032,"activeCount":95},[3033],{"nctId":3007,"briefTitle":3008,"status":105,"phases":3034,"primaryCompletion":3010,"completion":3010,"start":3011,"enrollment":3012,"conditions":3035,"interventions":3036},[84],[18,3014,3015,3016],[2998,3018],{"trials":3038,"activeCount":95},[],{"trials":3040,"activeCount":95},[],{"trials":3042,"activeCount":95},[],{"intervention":3044,"totalTrials":135,"cells":3045},"semaglutide",{"EARLY_PHASE1":3046,"PHASE1":3048,"PHASE2":3050,"PHASE3":3062,"PHASE4":3064,"NA":3066},{"trials":3047,"activeCount":95},[],{"trials":3049,"activeCount":95},[],{"trials":3051,"activeCount":95},[3052],{"nctId":3053,"briefTitle":3054,"status":118,"phases":3055,"primaryCompletion":3056,"completion":3056,"start":3057,"enrollment":239,"conditions":3058,"interventions":3060},"NCT07610174","Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves",[84],"2026-04-29","2025-06-02",[857,3059],"Heart Valve Prosthesis",[3044,3061],"Dapagliflozin",{"trials":3063,"activeCount":95},[],{"trials":3065,"activeCount":95},[],{"trials":3067,"activeCount":95},[],{"intervention":3061,"totalTrials":135,"cells":3069},{"EARLY_PHASE1":3070,"PHASE1":3072,"PHASE2":3074,"PHASE3":3080,"PHASE4":3082,"NA":3084},{"trials":3071,"activeCount":95},[],{"trials":3073,"activeCount":95},[],{"trials":3075,"activeCount":95},[3076],{"nctId":3053,"briefTitle":3054,"status":118,"phases":3077,"primaryCompletion":3056,"completion":3056,"start":3057,"enrollment":239,"conditions":3078,"interventions":3079},[84],[857,3059],[3044,3061],{"trials":3081,"activeCount":95},[],{"trials":3083,"activeCount":95},[],{"trials":3085,"activeCount":95},[],{"intervention":3087,"totalTrials":135,"cells":3088},"Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg",{"EARLY_PHASE1":3089,"PHASE1":3091,"PHASE2":3093,"PHASE3":3103,"PHASE4":3105,"NA":3107},{"trials":3090,"activeCount":95},[],{"trials":3092,"activeCount":95},[],{"trials":3094,"activeCount":95},[3095],{"nctId":3096,"briefTitle":3097,"status":105,"phases":3098,"primaryCompletion":1764,"completion":3099,"start":1766,"enrollment":2255,"conditions":3100,"interventions":3101},"NCT04578236","Efficacy of Aerosol Combination Therapy of 13 Cis Retinoic Acid and Captopril for Treating Covid-19 Patients Via Indirect Inhibition of Transmembrane Protease, Serine 2 (TMPRSS2)",[84],"2021-01",[1769],[3087,3102],"Drug: Standard treatment Standard treatment",{"trials":3104,"activeCount":95},[],{"trials":3106,"activeCount":95},[],{"trials":3108,"activeCount":95},[],{"intervention":3102,"totalTrials":135,"cells":3110},{"EARLY_PHASE1":3111,"PHASE1":3113,"PHASE2":3115,"PHASE3":3121,"PHASE4":3123,"NA":3125},{"trials":3112,"activeCount":95},[],{"trials":3114,"activeCount":95},[],{"trials":3116,"activeCount":95},[3117],{"nctId":3096,"briefTitle":3097,"status":105,"phases":3118,"primaryCompletion":1764,"completion":3099,"start":1766,"enrollment":2255,"conditions":3119,"interventions":3120},[84],[1769],[3087,3102],{"trials":3122,"activeCount":95},[],{"trials":3124,"activeCount":95},[],{"trials":3126,"activeCount":95},[],{"intervention":3128,"totalTrials":135,"cells":3129},"WJ-MSC- Exosomes",{"EARLY_PHASE1":3130,"PHASE1":3132,"PHASE2":3146,"PHASE3":3148,"PHASE4":3150,"NA":3152},{"trials":3131,"activeCount":95},[],{"trials":3133,"activeCount":95},[3134],{"nctId":3135,"briefTitle":3136,"status":118,"phases":3137,"primaryCompletion":3138,"completion":3139,"start":3140,"enrollment":3141,"conditions":3142,"interventions":3144},"NCT06812637","Efficacy and Safety of Wharton's Jelly-Derived Mesenchymal Stem Cell Exosomes in the Treatment of Diabetic Foot Ulcers: A Double-blinded Randomized Controlled Clinical Trial",[83],"2024-06-06","2024-09-02","2024-04-06",110,[3143,968],"Diabetic Foot Ulcer (DFU)",[3128,3145],"SOC",{"trials":3147,"activeCount":95},[],{"trials":3149,"activeCount":95},[],{"trials":3151,"activeCount":95},[],{"trials":3153,"activeCount":95},[],{"intervention":3145,"totalTrials":135,"cells":3155},{"EARLY_PHASE1":3156,"PHASE1":3158,"PHASE2":3164,"PHASE3":3166,"PHASE4":3168,"NA":3170},{"trials":3157,"activeCount":95},[],{"trials":3159,"activeCount":95},[3160],{"nctId":3135,"briefTitle":3136,"status":118,"phases":3161,"primaryCompletion":3138,"completion":3139,"start":3140,"enrollment":3141,"conditions":3162,"interventions":3163},[83],[3143,968],[3128,3145],{"trials":3165,"activeCount":95},[],{"trials":3167,"activeCount":95},[],{"trials":3169,"activeCount":95},[],{"trials":3171,"activeCount":95},[],{"intervention":3173,"totalTrials":135,"cells":3174},"Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP",{"EARLY_PHASE1":3175,"PHASE1":3177,"PHASE2":3185,"PHASE3":3187,"PHASE4":3189,"NA":3191},{"trials":3176,"activeCount":95},[],{"trials":3178,"activeCount":95},[3179],{"nctId":3180,"briefTitle":3181,"status":105,"phases":3182,"primaryCompletion":2280,"completion":2279,"start":2265,"enrollment":1519,"conditions":3183,"interventions":3184},"NCT04375046","Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications Better Than Recombinant Human ACE2",[83],[30],[3173],{"trials":3186,"activeCount":95},[],{"trials":3188,"activeCount":95},[],{"trials":3190,"activeCount":95},[],{"trials":3192,"activeCount":95},[],{"intervention":3194,"totalTrials":135,"cells":3195},"Application of minocycline and hyaluronic acid gel.",{"EARLY_PHASE1":3196,"PHASE1":3198,"PHASE2":3210,"PHASE3":3212,"PHASE4":3214,"NA":3216},{"trials":3197,"activeCount":95},[],{"trials":3199,"activeCount":95},[3200],{"nctId":3201,"briefTitle":3202,"status":118,"phases":3203,"primaryCompletion":1516,"completion":1517,"start":3204,"enrollment":2090,"conditions":3205,"interventions":3208},"NCT06997731","Clinical Efficacy of Local Delivery of Minocycline and Hyaluronan Gel to Treat Periodontitis in Diabetic Patients",[83],"2023-05-20",[3206,3207],"Periodontitis and Diabetes","Periodontitis",[3194,3209],"local application of placebo gel",{"trials":3211,"activeCount":95},[],{"trials":3213,"activeCount":95},[],{"trials":3215,"activeCount":95},[],{"trials":3217,"activeCount":95},[],{"intervention":3209,"totalTrials":135,"cells":3219},{"EARLY_PHASE1":3220,"PHASE1":3222,"PHASE2":3228,"PHASE3":3230,"PHASE4":3232,"NA":3234},{"trials":3221,"activeCount":95},[],{"trials":3223,"activeCount":95},[3224],{"nctId":3201,"briefTitle":3202,"status":118,"phases":3225,"primaryCompletion":1516,"completion":1517,"start":3204,"enrollment":2090,"conditions":3226,"interventions":3227},[83],[3206,3207],[3194,3209],{"trials":3229,"activeCount":95},[],{"trials":3231,"activeCount":95},[],{"trials":3233,"activeCount":95},[],{"trials":3235,"activeCount":95},[],{"intervention":3237,"totalTrials":135,"cells":3238},"SnPP Protoporphyrin plus Sunlight exposure",{"EARLY_PHASE1":3239,"PHASE1":3241,"PHASE2":3252,"PHASE3":3254,"PHASE4":3256,"NA":3258},{"trials":3240,"activeCount":95},[],{"trials":3242,"activeCount":95},[3243],{"nctId":3244,"briefTitle":3245,"status":105,"phases":3246,"primaryCompletion":2254,"completion":1766,"start":3247,"enrollment":3248,"conditions":3249,"interventions":3250},"NCT04371822","Efficacy of Sunlight Activated Synthetic Porphyrin in COVID-19 Infected Patients",[83],"2020-08",56,[30],[3237,3237,3237,3251],"Sulfonatoporphyrin(TPPS) plus Sunlight exposure.",{"trials":3253,"activeCount":95},[],{"trials":3255,"activeCount":95},[],{"trials":3257,"activeCount":95},[],{"trials":3259,"activeCount":95},[],{"intervention":3251,"totalTrials":135,"cells":3261},{"EARLY_PHASE1":3262,"PHASE1":3264,"PHASE2":3270,"PHASE3":3272,"PHASE4":3274,"NA":3276},{"trials":3263,"activeCount":95},[],{"trials":3265,"activeCount":95},[3266],{"nctId":3244,"briefTitle":3245,"status":105,"phases":3267,"primaryCompletion":2254,"completion":1766,"start":3247,"enrollment":3248,"conditions":3268,"interventions":3269},[83],[30],[3237,3237,3237,3251],{"trials":3271,"activeCount":95},[],{"trials":3273,"activeCount":95},[],{"trials":3275,"activeCount":95},[],{"trials":3277,"activeCount":95},[],{"intervention":3279,"totalTrials":135,"cells":3280},"Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid",{"EARLY_PHASE1":3281,"PHASE1":3283,"PHASE2":3292,"PHASE3":3294,"PHASE4":3296,"NA":3298},{"trials":3282,"activeCount":95},[],{"trials":3284,"activeCount":95},[3285],{"nctId":3286,"briefTitle":3287,"status":105,"phases":3288,"primaryCompletion":2280,"completion":2279,"start":2265,"enrollment":1519,"conditions":3289,"interventions":3291},"NCT04382950","Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications",[83],[3290],"COVID",[3279],{"trials":3293,"activeCount":95},[],{"trials":3295,"activeCount":95},[],{"trials":3297,"activeCount":95},[],{"trials":3299,"activeCount":95},[],{"intervention":3301,"totalTrials":135,"cells":3302},"solidosin",{"EARLY_PHASE1":3303,"PHASE1":3317,"PHASE2":3319,"PHASE3":3321,"PHASE4":3323,"NA":3325},{"trials":3304,"activeCount":95},[3305],{"nctId":3306,"briefTitle":3307,"status":118,"phases":3308,"primaryCompletion":342,"completion":391,"start":3309,"enrollment":3310,"conditions":3311,"interventions":3313},"NCT07447518","Double j Stent Related Symptoms",[82],"2022-09-22",535,[3312],"Lower Urinary Tract Symptoms",[3314,3301,3315,3316],"Tadalafil 5mg","Solfenacin","Mirabegron",{"trials":3318,"activeCount":95},[],{"trials":3320,"activeCount":95},[],{"trials":3322,"activeCount":95},[],{"trials":3324,"activeCount":95},[],{"trials":3326,"activeCount":95},[],{"intervention":3315,"totalTrials":135,"cells":3328},{"EARLY_PHASE1":3329,"PHASE1":3335,"PHASE2":3337,"PHASE3":3339,"PHASE4":3341,"NA":3343},{"trials":3330,"activeCount":95},[3331],{"nctId":3306,"briefTitle":3307,"status":118,"phases":3332,"primaryCompletion":342,"completion":391,"start":3309,"enrollment":3310,"conditions":3333,"interventions":3334},[82],[3312],[3314,3301,3315,3316],{"trials":3336,"activeCount":95},[],{"trials":3338,"activeCount":95},[],{"trials":3340,"activeCount":95},[],{"trials":3342,"activeCount":95},[],{"trials":3344,"activeCount":95},[],{"intervention":3316,"totalTrials":135,"cells":3346},{"EARLY_PHASE1":3347,"PHASE1":3353,"PHASE2":3355,"PHASE3":3357,"PHASE4":3359,"NA":3361},{"trials":3348,"activeCount":95},[3349],{"nctId":3306,"briefTitle":3307,"status":118,"phases":3350,"primaryCompletion":342,"completion":391,"start":3309,"enrollment":3310,"conditions":3351,"interventions":3352},[82],[3312],[3314,3301,3315,3316],{"trials":3354,"activeCount":95},[],{"trials":3356,"activeCount":95},[],{"trials":3358,"activeCount":95},[],{"trials":3360,"activeCount":95},[],{"trials":3362,"activeCount":95},[],{"intervention":2422,"totalTrials":461,"cells":3364},{"EARLY_PHASE1":3365,"PHASE1":3367,"PHASE2":3369,"PHASE3":3371,"PHASE4":3377,"NA":3379},{"trials":3366,"activeCount":95},[],{"trials":3368,"activeCount":95},[],{"trials":3370,"activeCount":95},[],{"trials":3372,"activeCount":95},[3373],{"nctId":2413,"briefTitle":2414,"status":118,"phases":3374,"primaryCompletion":2416,"completion":2417,"start":2418,"enrollment":779,"conditions":3375,"interventions":3376},[85],[2420],[2422,2402],{"trials":3378,"activeCount":95},[],{"trials":3380,"activeCount":95},[3381],{"nctId":3382,"briefTitle":3383,"status":118,"phases":3384,"primaryCompletion":3385,"completion":3386,"start":2194,"enrollment":1195,"conditions":3387,"interventions":3389},"NCT04430413","Effect of Platelet Rich Plasma on Healing of Operated Pilonidal Sinus by Open Method",[87],"2019-12-01","2019-12-31",[3388],"Pilonidal Disease of Natal Cleft",[2422],{"intervention":3391,"totalTrials":461,"cells":3392},"Morphine",{"EARLY_PHASE1":3393,"PHASE1":3395,"PHASE2":3397,"PHASE3":3399,"PHASE4":3401,"NA":3403},{"trials":3394,"activeCount":95},[],{"trials":3396,"activeCount":95},[],{"trials":3398,"activeCount":95},[],{"trials":3400,"activeCount":95},[],{"trials":3402,"activeCount":95},[],{"trials":3404,"activeCount":95},[3405,3418],{"nctId":3406,"briefTitle":3407,"status":118,"phases":3408,"primaryCompletion":3409,"completion":3409,"start":3410,"enrollment":3411,"conditions":3412,"interventions":3417},"NCT07012590","Morphine and Dexmedetomidine as Adjuvants to Bupivacaine in Ultrasound-guided Erector Spinae Plane Block for Open Subcostal Renal Surgeries",[87],"2024-07-31","2023-05-01",147,[3391,18,3413,3414,3415,24,3416],"Adjuvants","Bupivacaine","Ultrasound","Open Subcostal Renal Surgeries",[3391,18],{"nctId":3419,"briefTitle":3420,"status":118,"phases":3421,"primaryCompletion":3422,"completion":3422,"start":3423,"enrollment":855,"conditions":3424,"interventions":3426},"NCT06422182","Erector Spinae Plane Block in Radical Cystectomy",[87],"2024-01-15","2021-07-25",[24,3425],"Radical Cystectomy",[3427,3391],"Bupivacain 25%",{"intervention":18,"totalTrials":461,"cells":3429},{"EARLY_PHASE1":3430,"PHASE1":3432,"PHASE2":3434,"PHASE3":3436,"PHASE4":3438,"NA":3444},{"trials":3431,"activeCount":95},[],{"trials":3433,"activeCount":95},[],{"trials":3435,"activeCount":95},[],{"trials":3437,"activeCount":95},[],{"trials":3439,"activeCount":95},[3440],{"nctId":1887,"briefTitle":1888,"status":105,"phases":3441,"primaryCompletion":1890,"completion":1890,"start":1891,"enrollment":1060,"conditions":3442,"interventions":3443},[86],[1893,18,1874,1894,1895,1896],[18,1874,1898],{"trials":3445,"activeCount":95},[3446],{"nctId":3406,"briefTitle":3407,"status":118,"phases":3447,"primaryCompletion":3409,"completion":3409,"start":3410,"enrollment":3411,"conditions":3448,"interventions":3449},[87],[3391,18,3413,3414,3415,24,3416],[3391,18],{"intervention":3314,"totalTrials":461,"cells":3451},{"EARLY_PHASE1":3452,"PHASE1":3458,"PHASE2":3460,"PHASE3":3462,"PHASE4":3464,"NA":3466},{"trials":3453,"activeCount":95},[3454],{"nctId":3306,"briefTitle":3307,"status":118,"phases":3455,"primaryCompletion":342,"completion":391,"start":3309,"enrollment":3310,"conditions":3456,"interventions":3457},[82],[3312],[3314,3301,3315,3316],{"trials":3459,"activeCount":95},[],{"trials":3461,"activeCount":95},[],{"trials":3463,"activeCount":95},[],{"trials":3465,"activeCount":95},[],{"trials":3467,"activeCount":95},[3468],{"nctId":3469,"briefTitle":3470,"status":118,"phases":3471,"primaryCompletion":383,"completion":383,"start":2620,"enrollment":3472,"conditions":3473,"interventions":3475},"NCT06788704","Tadalafil Daily Used Post Turp",[],270,[3474],"Erectile Dysfunction Following Urethral Surgery",[3314],{"intervention":3414,"totalTrials":461,"cells":3477},{"EARLY_PHASE1":3478,"PHASE1":3480,"PHASE2":3482,"PHASE3":3484,"PHASE4":3486,"NA":3488},{"trials":3479,"activeCount":95},[],{"trials":3481,"activeCount":95},[],{"trials":3483,"activeCount":95},[],{"trials":3485,"activeCount":95},[],{"trials":3487,"activeCount":95},[],{"trials":3489,"activeCount":95},[3490,3501],{"nctId":3491,"briefTitle":3492,"status":105,"phases":3493,"primaryCompletion":335,"completion":335,"start":3494,"enrollment":779,"conditions":3495,"interventions":3500},"NCT06276179","Epidural Oxycodone for Pain Management for Lower Limb Amputation",[87],"2024-02-24",[3496,3497,3498,3499],"Epidural","Oxycodone","Pain","Lower Limb Amputation",[3497,3414],{"nctId":3502,"briefTitle":3503,"status":118,"phases":3504,"primaryCompletion":3505,"completion":3505,"start":3506,"enrollment":1060,"conditions":3507,"interventions":3509},"NCT06020781","Efficacy and Safety of Dexmedetomidine to Bupivacaine in Supraclavicular Brachial Plexus Block",[87],"2024-03-11","2023-10-09",[18,3414,3508],"Supraclavicular Brachial Plexus Block",[3510,3511,3512],"bupivacaine and dexmedetomidine.","bupivacaine only","bupivacaine",{"intervention":3514,"totalTrials":135,"cells":3515},"intranasal dexmedetomidine group",{"EARLY_PHASE1":3516,"PHASE1":3518,"PHASE2":3520,"PHASE3":3522,"PHASE4":3524,"NA":3526},{"trials":3517,"activeCount":95},[],{"trials":3519,"activeCount":95},[],{"trials":3521,"activeCount":95},[],{"trials":3523,"activeCount":95},[],{"trials":3525,"activeCount":95},[],{"trials":3527,"activeCount":95},[3528],{"nctId":3529,"briefTitle":3530,"status":105,"phases":3531,"primaryCompletion":381,"completion":381,"start":2089,"enrollment":1372,"conditions":3532,"interventions":3534},"NCT05595083","Intranasal vs. IV Dexmedetomidine in Endoscopic Sinus Surgery",[87],[3533,18],"Functional Endoscopic Sinus Surgery",[3514,3535],"intravouns dexmedetomidine group",{"intervention":3535,"totalTrials":135,"cells":3537},{"EARLY_PHASE1":3538,"PHASE1":3540,"PHASE2":3542,"PHASE3":3544,"PHASE4":3546,"NA":3548},{"trials":3539,"activeCount":95},[],{"trials":3541,"activeCount":95},[],{"trials":3543,"activeCount":95},[],{"trials":3545,"activeCount":95},[],{"trials":3547,"activeCount":95},[],{"trials":3549,"activeCount":95},[3550],{"nctId":3529,"briefTitle":3530,"status":105,"phases":3551,"primaryCompletion":381,"completion":381,"start":2089,"enrollment":1372,"conditions":3552,"interventions":3553},[87],[3533,18],[3514,3535],{"intervention":3555,"totalTrials":135,"cells":3556},"Muscle relaxants tizanidine",{"EARLY_PHASE1":3557,"PHASE1":3559,"PHASE2":3561,"PHASE3":3563,"PHASE4":3565,"NA":3567},{"trials":3558,"activeCount":95},[],{"trials":3560,"activeCount":95},[],{"trials":3562,"activeCount":95},[],{"trials":3564,"activeCount":95},[],{"trials":3566,"activeCount":95},[],{"trials":3568,"activeCount":95},[3569],{"nctId":3570,"briefTitle":3571,"status":118,"phases":3572,"primaryCompletion":3573,"completion":3573,"start":3574,"enrollment":779,"conditions":3575,"interventions":3577},"NCT07025187","the Effect of Integrated Neuomuscular Inhibition Technique on Adult Females With Cervicogenic Headache",[87],"2025-11-01","2025-06-16",[3576],"Cervicogenic Headache",[3555],{"intervention":3579,"totalTrials":135,"cells":3580},"Superficial cervical plexus block",{"EARLY_PHASE1":3581,"PHASE1":3583,"PHASE2":3585,"PHASE3":3587,"PHASE4":3589,"NA":3591},{"trials":3582,"activeCount":95},[],{"trials":3584,"activeCount":95},[],{"trials":3586,"activeCount":95},[],{"trials":3588,"activeCount":95},[],{"trials":3590,"activeCount":95},[],{"trials":3592,"activeCount":95},[3593],{"nctId":3594,"briefTitle":3595,"status":118,"phases":3596,"primaryCompletion":3597,"completion":3597,"start":2309,"enrollment":855,"conditions":3598,"interventions":3602},"NCT07057739","Fentanyl and Dexmedetomidine as Adjuvants to Bupivacaine in Ultrasound-guided Superficial Cervical Plexus Block in Thyroid Surgeries",[87],"2025-05-30",[3599,18,3413,3414,3415,3600,3601],"Fentanyl","Superficial Cervical Plexus Block","Thyroid Surgeries",[3579,3603,3604],"Superficial cervical plexus block + Fentanyl","Superficial cervical plexus block + Dexmedetomidine",{"intervention":3603,"totalTrials":135,"cells":3606},{"EARLY_PHASE1":3607,"PHASE1":3609,"PHASE2":3611,"PHASE3":3613,"PHASE4":3615,"NA":3617},{"trials":3608,"activeCount":95},[],{"trials":3610,"activeCount":95},[],{"trials":3612,"activeCount":95},[],{"trials":3614,"activeCount":95},[],{"trials":3616,"activeCount":95},[],{"trials":3618,"activeCount":95},[3619],{"nctId":3594,"briefTitle":3595,"status":118,"phases":3620,"primaryCompletion":3597,"completion":3597,"start":2309,"enrollment":855,"conditions":3621,"interventions":3622},[87],[3599,18,3413,3414,3415,3600,3601],[3579,3603,3604],{"intervention":3604,"totalTrials":135,"cells":3624},{"EARLY_PHASE1":3625,"PHASE1":3627,"PHASE2":3629,"PHASE3":3631,"PHASE4":3633,"NA":3635},{"trials":3626,"activeCount":95},[],{"trials":3628,"activeCount":95},[],{"trials":3630,"activeCount":95},[],{"trials":3632,"activeCount":95},[],{"trials":3634,"activeCount":95},[],{"trials":3636,"activeCount":95},[3637],{"nctId":3594,"briefTitle":3595,"status":118,"phases":3638,"primaryCompletion":3597,"completion":3597,"start":2309,"enrollment":855,"conditions":3639,"interventions":3640},[87],[3599,18,3413,3414,3415,3600,3601],[3579,3603,3604],{"intervention":3642,"totalTrials":135,"cells":3643},"Bupivacaine + Dexmedetomidine",{"EARLY_PHASE1":3644,"PHASE1":3646,"PHASE2":3648,"PHASE3":3650,"PHASE4":3652,"NA":3654},{"trials":3645,"activeCount":95},[],{"trials":3647,"activeCount":95},[],{"trials":3649,"activeCount":95},[],{"trials":3651,"activeCount":95},[],{"trials":3653,"activeCount":95},[],{"trials":3655,"activeCount":95},[3656],{"nctId":3657,"briefTitle":3658,"status":118,"phases":3659,"primaryCompletion":40,"completion":40,"start":3660,"enrollment":779,"conditions":3661,"interventions":3665},"NCT06737458","Serratus Anterior Plane Block Versus Erector Spinae Plane Block With Dexmedetomidine Added to Bupivacaine for Ultrasound-Guided Pain Management After Mastectomy",[87],"2023-07-01",[3662,24,18,3414,3415,3663,3664],"Serratus Anterior Plane Block","Pain Management","Mastectomy",[3642,3642],{"intervention":3667,"totalTrials":135,"cells":3668},"designed physical exercises only",{"EARLY_PHASE1":3669,"PHASE1":3671,"PHASE2":3673,"PHASE3":3675,"PHASE4":3677,"NA":3679},{"trials":3670,"activeCount":95},[],{"trials":3672,"activeCount":95},[],{"trials":3674,"activeCount":95},[],{"trials":3676,"activeCount":95},[],{"trials":3678,"activeCount":95},[],{"trials":3680,"activeCount":95},[3681],{"nctId":3682,"briefTitle":3683,"status":118,"phases":3684,"primaryCompletion":287,"completion":3685,"start":3573,"enrollment":3686,"conditions":3687,"interventions":3689},"NCT06939933","Effect of Aquatic Exercises on Muscle Strength and Quality of Life in Children With Sickle Cell Anemia",[87],"2025-12-30",50,[3688],"Sickle Cell Anemia in Children",[3667],{"intervention":3691,"totalTrials":135,"cells":3692},"Metoclopramide",{"EARLY_PHASE1":3693,"PHASE1":3695,"PHASE2":3697,"PHASE3":3699,"PHASE4":3701,"NA":3703},{"trials":3694,"activeCount":95},[],{"trials":3696,"activeCount":95},[],{"trials":3698,"activeCount":95},[],{"trials":3700,"activeCount":95},[],{"trials":3702,"activeCount":95},[],{"trials":3704,"activeCount":95},[3705],{"nctId":3706,"briefTitle":3707,"status":118,"phases":3708,"primaryCompletion":3709,"completion":3709,"start":1809,"enrollment":855,"conditions":3710,"interventions":3715},"NCT07519447","Gastric Residual Volume and Aspiration Risk Following Intravenous Metoclopramide in Fasted Diabetic Patients Undergoing Elective Surgery",[],"2025-09-01",[3711,3712,3691,3713,3714],"Gastric Residual Volume","Aspiration Risk","Fasted Diabetic Patients","Elective Surgery",[3691],{"intervention":3717,"totalTrials":135,"cells":3718},"CWP gel",{"EARLY_PHASE1":3719,"PHASE1":3721,"PHASE2":3723,"PHASE3":3725,"PHASE4":3727,"NA":3729},{"trials":3720,"activeCount":95},[],{"trials":3722,"activeCount":95},[],{"trials":3724,"activeCount":95},[],{"trials":3726,"activeCount":95},[],{"trials":3728,"activeCount":95},[],{"trials":3730,"activeCount":95},[3731],{"nctId":3732,"briefTitle":3733,"status":118,"phases":3734,"primaryCompletion":1809,"completion":1408,"start":1194,"enrollment":1149,"conditions":3735,"interventions":3737},"NCT06401798","Locally Delivered Whey Protein Nanoparticles Gel in Stage II Grade B Periodontitis",[87],[3736],"Periodontitis Chronic Localized Slight",[3717,3738],"NCWP gel",{"intervention":3738,"totalTrials":135,"cells":3740},{"EARLY_PHASE1":3741,"PHASE1":3743,"PHASE2":3745,"PHASE3":3747,"PHASE4":3749,"NA":3751},{"trials":3742,"activeCount":95},[],{"trials":3744,"activeCount":95},[],{"trials":3746,"activeCount":95},[],{"trials":3748,"activeCount":95},[],{"trials":3750,"activeCount":95},[],{"trials":3752,"activeCount":95},[3753],{"nctId":3732,"briefTitle":3733,"status":118,"phases":3754,"primaryCompletion":1809,"completion":1408,"start":1194,"enrollment":1149,"conditions":3755,"interventions":3756},[87],[3736],[3717,3738],{"intervention":3758,"totalTrials":135,"cells":3759},"spirulina gel",{"EARLY_PHASE1":3760,"PHASE1":3762,"PHASE2":3764,"PHASE3":3766,"PHASE4":3768,"NA":3770},{"trials":3761,"activeCount":95},[],{"trials":3763,"activeCount":95},[],{"trials":3765,"activeCount":95},[],{"trials":3767,"activeCount":95},[],{"trials":3769,"activeCount":95},[],{"trials":3771,"activeCount":95},[3772],{"nctId":3773,"briefTitle":3774,"status":118,"phases":3775,"primaryCompletion":3776,"completion":3777,"start":164,"enrollment":779,"conditions":3778,"interventions":3779},"NCT06016933","Effect of Spirulina on Periodontitis",[87],"2023-03-01","2023-07-22",[3207],[3758],{"intervention":3497,"totalTrials":135,"cells":3781},{"EARLY_PHASE1":3782,"PHASE1":3784,"PHASE2":3786,"PHASE3":3788,"PHASE4":3790,"NA":3792},{"trials":3783,"activeCount":95},[],{"trials":3785,"activeCount":95},[],{"trials":3787,"activeCount":95},[],{"trials":3789,"activeCount":95},[],{"trials":3791,"activeCount":95},[],{"trials":3793,"activeCount":95},[3794],{"nctId":3491,"briefTitle":3492,"status":105,"phases":3795,"primaryCompletion":335,"completion":335,"start":3494,"enrollment":779,"conditions":3796,"interventions":3797},[87],[3496,3497,3498,3499],[3497,3414],{"intervention":3799,"totalTrials":135,"cells":3800},"Mirtazapine + Bupivacaine + Morphine",{"EARLY_PHASE1":3801,"PHASE1":3803,"PHASE2":3805,"PHASE3":3807,"PHASE4":3809,"NA":3811},{"trials":3802,"activeCount":95},[],{"trials":3804,"activeCount":95},[],{"trials":3806,"activeCount":95},[],{"trials":3808,"activeCount":95},[],{"trials":3810,"activeCount":95},[],{"trials":3812,"activeCount":95},[3813],{"nctId":3814,"briefTitle":3815,"status":118,"phases":3816,"primaryCompletion":366,"completion":366,"start":342,"enrollment":2621,"conditions":3817,"interventions":3823},"NCT06681805","Prophylactic Mirtazapine and Different Doses of Intrathecal Morphine in Preventing Nausea and Vomiting After Cesarean Section",[87],[3818,3819,3820,3391,3821,3822],"Prophylactic","Mirtazapine","Intrathecal","Nausea","Vomiting",[3799,3799],{"intervention":3825,"totalTrials":135,"cells":3826},"Hypopressive Exercises and",{"EARLY_PHASE1":3827,"PHASE1":3829,"PHASE2":3831,"PHASE3":3833,"PHASE4":3835,"NA":3837},{"trials":3828,"activeCount":95},[],{"trials":3830,"activeCount":95},[],{"trials":3832,"activeCount":95},[],{"trials":3834,"activeCount":95},[],{"trials":3836,"activeCount":95},[],{"trials":3838,"activeCount":95},[3839],{"nctId":3840,"briefTitle":3841,"status":105,"phases":3842,"primaryCompletion":3843,"completion":3844,"start":1810,"enrollment":3845,"conditions":3846,"interventions":3848},"NCT06259474","Effect of Hypopressive Exercises on Postpartum Backache and Functional Disability",[87],"2024-09","2024-11",47,[3847],"Low Back Pain",[3825],{"intervention":3427,"totalTrials":135,"cells":3850},{"EARLY_PHASE1":3851,"PHASE1":3853,"PHASE2":3855,"PHASE3":3857,"PHASE4":3859,"NA":3861},{"trials":3852,"activeCount":95},[],{"trials":3854,"activeCount":95},[],{"trials":3856,"activeCount":95},[],{"trials":3858,"activeCount":95},[],{"trials":3860,"activeCount":95},[],{"trials":3862,"activeCount":95},[3863],{"nctId":3419,"briefTitle":3420,"status":118,"phases":3864,"primaryCompletion":3422,"completion":3422,"start":3423,"enrollment":855,"conditions":3865,"interventions":3866},[87],[24,3425],[3427,3391],{"intervention":3510,"totalTrials":135,"cells":3868},{"EARLY_PHASE1":3869,"PHASE1":3871,"PHASE2":3873,"PHASE3":3875,"PHASE4":3877,"NA":3879},{"trials":3870,"activeCount":95},[],{"trials":3872,"activeCount":95},[],{"trials":3874,"activeCount":95},[],{"trials":3876,"activeCount":95},[],{"trials":3878,"activeCount":95},[],{"trials":3880,"activeCount":95},[3881],{"nctId":3502,"briefTitle":3503,"status":118,"phases":3882,"primaryCompletion":3505,"completion":3505,"start":3506,"enrollment":1060,"conditions":3883,"interventions":3884},[87],[18,3414,3508],[3510,3511,3512],{"intervention":3511,"totalTrials":135,"cells":3886},{"EARLY_PHASE1":3887,"PHASE1":3889,"PHASE2":3891,"PHASE3":3893,"PHASE4":3895,"NA":3897},{"trials":3888,"activeCount":95},[],{"trials":3890,"activeCount":95},[],{"trials":3892,"activeCount":95},[],{"trials":3894,"activeCount":95},[],{"trials":3896,"activeCount":95},[],{"trials":3898,"activeCount":95},[3899],{"nctId":3502,"briefTitle":3503,"status":118,"phases":3900,"primaryCompletion":3505,"completion":3505,"start":3506,"enrollment":1060,"conditions":3901,"interventions":3902},[87],[18,3414,3508],[3510,3511,3512],{"intervention":3904,"totalTrials":135,"cells":3905},"Tranexamic acid",{"EARLY_PHASE1":3906,"PHASE1":3908,"PHASE2":3910,"PHASE3":3912,"PHASE4":3914,"NA":3916},{"trials":3907,"activeCount":95},[],{"trials":3909,"activeCount":95},[],{"trials":3911,"activeCount":95},[],{"trials":3913,"activeCount":95},[],{"trials":3915,"activeCount":95},[],{"trials":3917,"activeCount":95},[3918],{"nctId":3919,"briefTitle":3920,"status":105,"phases":3921,"primaryCompletion":393,"completion":3922,"start":3923,"enrollment":511,"conditions":3924,"interventions":3927},"NCT04367155","Efficacy of Tranexamic Acid on Blood Loss During Percutaneous Nephrolithotomy.",[87],"2022-03-01","2019-09-01",[3925,3926],"Renal Stones","Nephrolithiasis",[3904],{"intervention":3929,"totalTrials":135,"cells":3930},"Doxylamine and Pyridoxine",{"EARLY_PHASE1":3931,"PHASE1":3933,"PHASE2":3935,"PHASE3":3937,"PHASE4":3939,"NA":3941},{"trials":3932,"activeCount":95},[],{"trials":3934,"activeCount":95},[],{"trials":3936,"activeCount":95},[],{"trials":3938,"activeCount":95},[],{"trials":3940,"activeCount":95},[],{"trials":3942,"activeCount":95},[3943],{"nctId":3944,"briefTitle":3945,"status":118,"phases":3946,"primaryCompletion":1370,"completion":1370,"start":3947,"enrollment":3948,"conditions":3949,"interventions":3951},"NCT06259747","Therapeutic Implications of Acutaping on Nausea and Vomiting During Pregnancy",[87],"2023-02-03",27,[3821,3950],"Vomiting of Pregnancy",[3929],{"intervention":3953,"totalTrials":135,"cells":3954},"camel whey protein gel",{"EARLY_PHASE1":3955,"PHASE1":3957,"PHASE2":3959,"PHASE3":3961,"PHASE4":3963,"NA":3965},{"trials":3956,"activeCount":95},[],{"trials":3958,"activeCount":95},[],{"trials":3960,"activeCount":95},[],{"trials":3962,"activeCount":95},[],{"trials":3964,"activeCount":95},[],{"trials":3966,"activeCount":95},[3967],{"nctId":3968,"briefTitle":3969,"status":118,"phases":3970,"primaryCompletion":3971,"completion":3972,"start":3973,"enrollment":2090,"conditions":3974,"interventions":3977},"NCT04886011","Camel Whey Protein Gel for the Treatment of Aphthous Ulcer",[87],"2021-10-15","2021-11-30","2021-05-15",[3975,3976],"Aphthous Stomatitis, Recurrent","Antioxidative Stress",[3953]]